Skip to main content
Erschienen in: Endocrine 3/2014

01.08.2014 | Review

Harmful effects of functional hypercortisolism: a working hypothesis

verfasst von: Giacomo Tirabassi, Marco Boscaro, Giorgio Arnaldi

Erschienen in: Endocrine | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Functional hypercortisolism (FH) is caused by conditions able to chronically activate hypothalamic–pituitary–adrenal axis and usually occurs in cases of major depression, anorexia nervosa, bulimia nervosa, alcoholism, diabetes mellitus, simple obesity, polycystic ovary syndrome, obstructive sleep apnea syndrome, panic disorder, generalized anxiety disorder, shift work, and end-stage renal disease. Most of these states belong to pseudo-Cushing disease, a condition which is difficult to distinguish from Cushing’s syndrome and characterized not only by biochemical findings but also by objective ones that can be attributed to hypercortisolism (e.g., striae rubrae, central obesity, skin atrophy, easy bruising, etc.). This hormonal imbalance, although reversible and generally mild, could mediate some systemic complications, mainly but not only of a metabolic/cardiovascular nature, which are present in these states and are largely the same as those present in Cushing’s syndrome. In this review we aim to discuss the evidence suggesting the emerging negative role for FH.
Literatur
1.
Zurück zum Zitat C. Tsigos, G.P. Chousos, Hypothalamic–pituitary–adrenal axis, neuroendocrine factors and stress. J. Psychosom. Res. 53, 865–871 (2002)PubMed C. Tsigos, G.P. Chousos, Hypothalamic–pituitary–adrenal axis, neuroendocrine factors and stress. J. Psychosom. Res. 53, 865–871 (2002)PubMed
2.
Zurück zum Zitat G. Arnaldi, T. Mancini, G. Tirabassi, L. Trementino, M. Boscaro, Advances in the epidemiology, pathogenesis, and management of Cushing’s syndrome complications. J. Endocrinol. Invest. 35, 434–448 (2012)PubMed G. Arnaldi, T. Mancini, G. Tirabassi, L. Trementino, M. Boscaro, Advances in the epidemiology, pathogenesis, and management of Cushing’s syndrome complications. J. Endocrinol. Invest. 35, 434–448 (2012)PubMed
3.
Zurück zum Zitat G. Arnaldi, A. Angeli, A.B. Atkinson, X. Bertagna, F. Cavagnini, G.P. Chrousos, G.A. Fava, J.W. Findling, R.C. Gaillard, A.B. Grossman, B. Kola, A. Lacroix, T. Mancini, F. Mantero, J. Newell-Price, L.K. Nieman, N. Sonino, M.L. Vance, A. Giustina, M. Boscaro, Diagnosis and complications of Cushing’s syndrome: a consensus statement. J. Clin. Endocrinol. Metab. 88, 5593–5602 (2003)PubMed G. Arnaldi, A. Angeli, A.B. Atkinson, X. Bertagna, F. Cavagnini, G.P. Chrousos, G.A. Fava, J.W. Findling, R.C. Gaillard, A.B. Grossman, B. Kola, A. Lacroix, T. Mancini, F. Mantero, J. Newell-Price, L.K. Nieman, N. Sonino, M.L. Vance, A. Giustina, M. Boscaro, Diagnosis and complications of Cushing’s syndrome: a consensus statement. J. Clin. Endocrinol. Metab. 88, 5593–5602 (2003)PubMed
4.
Zurück zum Zitat G. Arnaldi, G. Tirabassi, R. Papa, G. Furlani, L. Trementino, M. Cardinaletti, E. Faloia, M. Boscaro, Human corticotropin releasing hormone test performance in the differential diagnosis between Cushing’s disease and pseudo-Cushing state is enhanced by combined ACTH and cortisol analysis. Eur. J. Endocrinol. 160, 891–898 (2009)PubMed G. Arnaldi, G. Tirabassi, R. Papa, G. Furlani, L. Trementino, M. Cardinaletti, E. Faloia, M. Boscaro, Human corticotropin releasing hormone test performance in the differential diagnosis between Cushing’s disease and pseudo-Cushing state is enhanced by combined ACTH and cortisol analysis. Eur. J. Endocrinol. 160, 891–898 (2009)PubMed
5.
Zurück zum Zitat G. Tirabassi, E. Faloia, R. Papa, G. Furlani, M. Boscaro, G. Arnaldi, Use of the desmopressin test in the differential diagnosis of pseudo-Cushing state from Cushing’s disease. J. Clin. Endocrinol. Metab. 95, 1115–1122 (2010)PubMed G. Tirabassi, E. Faloia, R. Papa, G. Furlani, M. Boscaro, G. Arnaldi, Use of the desmopressin test in the differential diagnosis of pseudo-Cushing state from Cushing’s disease. J. Clin. Endocrinol. Metab. 95, 1115–1122 (2010)PubMed
6.
Zurück zum Zitat G. Tirabassi, R. Papa, E. Faloia, M. Boscaro, G. Arnaldi, Corticotrophin-releasing hormone and desmopressin tests in the differential diagnosis between Cushing’s disease and pseudo-Cushing state: a comparative study. Clin. Endocrinol. (Oxf) 75, 666–672 (2011) G. Tirabassi, R. Papa, E. Faloia, M. Boscaro, G. Arnaldi, Corticotrophin-releasing hormone and desmopressin tests in the differential diagnosis between Cushing’s disease and pseudo-Cushing state: a comparative study. Clin. Endocrinol. (Oxf) 75, 666–672 (2011)
7.
Zurück zum Zitat L.K. Nieman, B.M. Biller, J.W. Findling, J. Newell-Price, M.O. Savage, P.M. Stewart, V.M. Montori, The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 93, 1526–1540 (2008)PubMedCentralPubMed L.K. Nieman, B.M. Biller, J.W. Findling, J. Newell-Price, M.O. Savage, P.M. Stewart, V.M. Montori, The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 93, 1526–1540 (2008)PubMedCentralPubMed
8.
Zurück zum Zitat S.A. Doi, J. Clark, A.W. Russell, Concordance of the late night salivary cortisol in patients with Cushing’s syndrome and elevated urine-free cortisol. Endocrine 43, 327–333 (2013)PubMed S.A. Doi, J. Clark, A.W. Russell, Concordance of the late night salivary cortisol in patients with Cushing’s syndrome and elevated urine-free cortisol. Endocrine 43, 327–333 (2013)PubMed
9.
Zurück zum Zitat H. Raff, Update on late-night salivary cortisol for the diagnosis of Cushing’s syndrome: methodological considerations. Endocrine 44, 346–349 (2013)PubMed H. Raff, Update on late-night salivary cortisol for the diagnosis of Cushing’s syndrome: methodological considerations. Endocrine 44, 346–349 (2013)PubMed
10.
Zurück zum Zitat H. Raff, Salivary cortisol and the diagnosis of Cushing’s syndrome: a coming of age. Endocrine 41, 353–354 (2012)PubMed H. Raff, Salivary cortisol and the diagnosis of Cushing’s syndrome: a coming of age. Endocrine 41, 353–354 (2012)PubMed
11.
Zurück zum Zitat Z.E. Belaya, A.V. Iljin, G.A. Melnichenko, L.Y. Rozhinskaya, N.V. Dragunova, L.K. Dzeranova, S.A. Butrova, E.A. Troshina, I.I. Dedov, Diagnostic performance of late-night salivary cortisol measured by automated electrochemiluminescence immunoassay in obese and overweight patients referred to exclude Cushing’s syndrome. Endocrine 41, 494–500 (2012)PubMed Z.E. Belaya, A.V. Iljin, G.A. Melnichenko, L.Y. Rozhinskaya, N.V. Dragunova, L.K. Dzeranova, S.A. Butrova, E.A. Troshina, I.I. Dedov, Diagnostic performance of late-night salivary cortisol measured by automated electrochemiluminescence immunoassay in obese and overweight patients referred to exclude Cushing’s syndrome. Endocrine 41, 494–500 (2012)PubMed
12.
Zurück zum Zitat C.A. Carrasco, M. García, M. Goycoolea, J. Cerda, J. Bertherat, O. Padilla, D. Meza, N. Wohllk, T. Quiroga, Reproducibility and performance of one or two samples of salivary cortisol in the diagnosis of Cushing’s syndrome using an automated immunoassay system. Endocrine 41, 487–493 (2012)PubMed C.A. Carrasco, M. García, M. Goycoolea, J. Cerda, J. Bertherat, O. Padilla, D. Meza, N. Wohllk, T. Quiroga, Reproducibility and performance of one or two samples of salivary cortisol in the diagnosis of Cushing’s syndrome using an automated immunoassay system. Endocrine 41, 487–493 (2012)PubMed
13.
Zurück zum Zitat M.D. Sullivan, P. O’Connor, P. Feeney, D. Hire, D.L. Simmons, D.W. Raisch, L.J. Fine, K.M. Narayan, M.K. Ali, W.J. Katon, Depression predicts all-cause mortality: epidemiological evaluation from the ACCORD HRQL substudy. Diabetes Care 35, 1708–1715 (2012)PubMedCentralPubMed M.D. Sullivan, P. O’Connor, P. Feeney, D. Hire, D.L. Simmons, D.W. Raisch, L.J. Fine, K.M. Narayan, M.K. Ali, W.J. Katon, Depression predicts all-cause mortality: epidemiological evaluation from the ACCORD HRQL substudy. Diabetes Care 35, 1708–1715 (2012)PubMedCentralPubMed
14.
Zurück zum Zitat M.S. Player, L.E. Peterson, Anxiety disorders, hypertension, and cardiovascular risk: a review. Int. J. Psychiatry Med. 41, 365–377 (2011)PubMed M.S. Player, L.E. Peterson, Anxiety disorders, hypertension, and cardiovascular risk: a review. Int. J. Psychiatry Med. 41, 365–377 (2011)PubMed
15.
Zurück zum Zitat H. Teede, A. Deeks, L. Moran, Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 8, 41 (2010)PubMedCentralPubMed H. Teede, A. Deeks, L. Moran, Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 8, 41 (2010)PubMedCentralPubMed
16.
Zurück zum Zitat A. Pan, N. Keum, O.I. Okereke, Q. Sun, M. Kivimaki, R.R. Rubin, F.B. Hu, Bidirectional association between depression and metabolic syndrome: a systematic review and meta-analysis of epidemiological studies. Diabetes Care 35, 1171–1180 (2012)PubMedCentralPubMed A. Pan, N. Keum, O.I. Okereke, Q. Sun, M. Kivimaki, R.R. Rubin, F.B. Hu, Bidirectional association between depression and metabolic syndrome: a systematic review and meta-analysis of epidemiological studies. Diabetes Care 35, 1171–1180 (2012)PubMedCentralPubMed
17.
Zurück zum Zitat C. Gragnoli, Depression and type 2 diabetes: cortisol pathway implication and investigational needs. J. Cell. Physiol. 227, 2318–2322 (2012)PubMed C. Gragnoli, Depression and type 2 diabetes: cortisol pathway implication and investigational needs. J. Cell. Physiol. 227, 2318–2322 (2012)PubMed
18.
Zurück zum Zitat D. Kopf, S. Westphal, C.W. Luley, S. Ritter, M. Gilles, B. Weber-Hamann, F. Lederbogen, H. Lehnert, F.A. Henn, I. Heuser, M. Deuschle, Lipid metabolism and insulin resistance in depressed patients: significance of weight, hypercortisolism, and antidepressant treatment. J. Clin. Psychopharmacol. 24, 527–531 (2004)PubMed D. Kopf, S. Westphal, C.W. Luley, S. Ritter, M. Gilles, B. Weber-Hamann, F. Lederbogen, H. Lehnert, F.A. Henn, I. Heuser, M. Deuschle, Lipid metabolism and insulin resistance in depressed patients: significance of weight, hypercortisolism, and antidepressant treatment. J. Clin. Psychopharmacol. 24, 527–531 (2004)PubMed
19.
Zurück zum Zitat Z. Rihmer, M. Arató, Depression and diabetes mellitus. A study of the relationship between serum cortisol and blood sugar levels in patients with endogenous depression. Neuropsychobiology 8, 315–318 (1982)PubMed Z. Rihmer, M. Arató, Depression and diabetes mellitus. A study of the relationship between serum cortisol and blood sugar levels in patients with endogenous depression. Neuropsychobiology 8, 315–318 (1982)PubMed
20.
Zurück zum Zitat B. Weber-Hamann, F. Hentschel, A. Kniest, M. Deuschle, M. Colla, F. Lederbogen, I. Heuser, Hypercortisolemic depression is associated with increased intra-abdominal fat. Psychosom. Med. 64, 274–277 (2002)PubMed B. Weber-Hamann, F. Hentschel, A. Kniest, M. Deuschle, M. Colla, F. Lederbogen, I. Heuser, Hypercortisolemic depression is associated with increased intra-abdominal fat. Psychosom. Med. 64, 274–277 (2002)PubMed
21.
Zurück zum Zitat G. Veen, E.J. Giltay, R.H. DeRijk, I.M. van Vliet, J. van Pelt, F.G. Zitman, Salivary cortisol, serum lipids, and adiposity in patients with depressive and anxiety disorders. Metabolism 58, 821–827 (2009)PubMed G. Veen, E.J. Giltay, R.H. DeRijk, I.M. van Vliet, J. van Pelt, F.G. Zitman, Salivary cortisol, serum lipids, and adiposity in patients with depressive and anxiety disorders. Metabolism 58, 821–827 (2009)PubMed
22.
Zurück zum Zitat B. Pfohl, M. Rederer, W. Coryell, D. Stangl, Association between post-dexamethasone cortisol level and blood pressure in depressed inpatients. J. Nerv. Ment. Dis. 179, 44–47 (1991)PubMed B. Pfohl, M. Rederer, W. Coryell, D. Stangl, Association between post-dexamethasone cortisol level and blood pressure in depressed inpatients. J. Nerv. Ment. Dis. 179, 44–47 (1991)PubMed
23.
Zurück zum Zitat N. Vogelzangs, K. Suthers, L. Ferrucci, E.M. Simonsick, A. Ble, M. Schrager, S. Bandinelli, F. Lauretani, S.V. Giannelli, B.W. Penninx, Hypercortisolemic depression is associated with the metabolic syndrome in late-life. Psychoneuroendocrinology 32, 151–159 (2007)PubMedCentralPubMed N. Vogelzangs, K. Suthers, L. Ferrucci, E.M. Simonsick, A. Ble, M. Schrager, S. Bandinelli, F. Lauretani, S.V. Giannelli, B.W. Penninx, Hypercortisolemic depression is associated with the metabolic syndrome in late-life. Psychoneuroendocrinology 32, 151–159 (2007)PubMedCentralPubMed
24.
Zurück zum Zitat S. Komatsu, M. Yamamoto, K. Arishima, Y. Eguchi, Maternal adrenocortical hormones maintain the early development of pancreatic B cells in the fetal rat. J. Anat. 193, 551–557 (1998)PubMedCentralPubMed S. Komatsu, M. Yamamoto, K. Arishima, Y. Eguchi, Maternal adrenocortical hormones maintain the early development of pancreatic B cells in the fetal rat. J. Anat. 193, 551–557 (1998)PubMedCentralPubMed
25.
Zurück zum Zitat J.N. Mann, J.H. Thakore, Melancholic depression and abdominal fat distribution: a mini-review. Stress 3, 1–15 (1999)PubMed J.N. Mann, J.H. Thakore, Melancholic depression and abdominal fat distribution: a mini-review. Stress 3, 1–15 (1999)PubMed
26.
Zurück zum Zitat J.H. Thakore, P.J. Richards, R.H. Reznek, A. Martin, T.G. Dinan, Increased intra-abdominal fat deposition in patients with major depressive illness as measured by computed tomography. Biol. Psychiatry 41, 1140–1142 (1997)PubMed J.H. Thakore, P.J. Richards, R.H. Reznek, A. Martin, T.G. Dinan, Increased intra-abdominal fat deposition in patients with major depressive illness as measured by computed tomography. Biol. Psychiatry 41, 1140–1142 (1997)PubMed
27.
Zurück zum Zitat B.W. Penninx, A.T. Beekman, A. Honig, D.J. Deeg, R.A. Schoevers, J.T. van Eijk, W. van Tilburg, Depression and cardiac mortality: results from a community-based longitudinal study. Arch. Gen. Psychiatry. 58, 221–227 (2001)PubMed B.W. Penninx, A.T. Beekman, A. Honig, D.J. Deeg, R.A. Schoevers, J.T. van Eijk, W. van Tilburg, Depression and cardiac mortality: results from a community-based longitudinal study. Arch. Gen. Psychiatry. 58, 221–227 (2001)PubMed
28.
Zurück zum Zitat M. Vythilingam, J. Chen, J.D. Bremner, C.M. Mazure, P.K. Maciejewski, J.C. Nelson, Psychotic depression and mortality. Am. J. Psychiatry 160, 574–576 (2003)PubMed M. Vythilingam, J. Chen, J.D. Bremner, C.M. Mazure, P.K. Maciejewski, J.C. Nelson, Psychotic depression and mortality. Am. J. Psychiatry 160, 574–576 (2003)PubMed
29.
Zurück zum Zitat W. Coryell, J. Fiedorowicz, M. Zimmerman, E. Young, HPA-axis hyperactivity and mortality in psychotic depressive disorder: preliminary findings. Psychoneuroendocrinology 33, 654–658 (2008)PubMedCentralPubMed W. Coryell, J. Fiedorowicz, M. Zimmerman, E. Young, HPA-axis hyperactivity and mortality in psychotic depressive disorder: preliminary findings. Psychoneuroendocrinology 33, 654–658 (2008)PubMedCentralPubMed
30.
Zurück zum Zitat M.H. Kamphuis, Depression and cardiovascular disease: the role of diet, lifestyle and health (Gildeprint BV, Enschede (the Netherlands), 2006) M.H. Kamphuis, Depression and cardiovascular disease: the role of diet, lifestyle and health (Gildeprint BV, Enschede (the Netherlands), 2006)
31.
Zurück zum Zitat A.J. Broadley, A. Korszun, E. Abdelaal, V. Moskvina, J. Deanfield, C.J. Jones, M.P. Frenneaux, Metyrapone improves endothelial dysfunction in patients with treated depression. J. Am. Coll. Cardiol. 48, 170–175 (2006)PubMed A.J. Broadley, A. Korszun, E. Abdelaal, V. Moskvina, J. Deanfield, C.J. Jones, M.P. Frenneaux, Metyrapone improves endothelial dysfunction in patients with treated depression. J. Am. Coll. Cardiol. 48, 170–175 (2006)PubMed
32.
Zurück zum Zitat L.J. Siever, T.W. Uhde, New studies and perspectives on the noradrenergic receptor system in depression: effects of the alpha 2-adrenergic agonist clonidine. Biol. Psychiatry 19, 131–156 (1984)PubMed L.J. Siever, T.W. Uhde, New studies and perspectives on the noradrenergic receptor system in depression: effects of the alpha 2-adrenergic agonist clonidine. Biol. Psychiatry 19, 131–156 (1984)PubMed
33.
Zurück zum Zitat A.J. Mitchell, T.R. Dening, Depression-related cognitive impairment: possibilities for its pharmacological treatment. J. Affect. Disord. 36, 79–87 (1996)PubMed A.J. Mitchell, T.R. Dening, Depression-related cognitive impairment: possibilities for its pharmacological treatment. J. Affect. Disord. 36, 79–87 (1996)PubMed
34.
35.
Zurück zum Zitat F. Thomson, M. Craighead, Innovative approaches for the treatment of depression: targeting the HPA axis. Neurochem. Res. 33, 691–707 (2008)PubMed F. Thomson, M. Craighead, Innovative approaches for the treatment of depression: targeting the HPA axis. Neurochem. Res. 33, 691–707 (2008)PubMed
36.
Zurück zum Zitat M.W. Strachan, R.M. Reynolds, B.M. Frier, R.J. Mitchell, J.F. Price, The role of metabolic derangements and glucocorticoid excess in the aetiology of cognitive impairment in type 2 diabetes. Implications for future therapeutic strategies. Diabetes Obes. Metab. 11, 407–414 (2009)PubMed M.W. Strachan, R.M. Reynolds, B.M. Frier, R.J. Mitchell, J.F. Price, The role of metabolic derangements and glucocorticoid excess in the aetiology of cognitive impairment in type 2 diabetes. Implications for future therapeutic strategies. Diabetes Obes. Metab. 11, 407–414 (2009)PubMed
37.
Zurück zum Zitat A.M. MacLullich, J.R. Seckl, Diabetes and cognitive decline: are steroids the missing link? Cell Metab. 7, 286–287 (2008)PubMed A.M. MacLullich, J.R. Seckl, Diabetes and cognitive decline: are steroids the missing link? Cell Metab. 7, 286–287 (2008)PubMed
38.
Zurück zum Zitat P.E. Stokes, The potential role of excessive cortisol induced by HPA hyperfunction in the pathogenesis of depression. Eur. Neuropsychopharmacol. 5(Suppl 1), 77–82 (1995)PubMed P.E. Stokes, The potential role of excessive cortisol induced by HPA hyperfunction in the pathogenesis of depression. Eur. Neuropsychopharmacol. 5(Suppl 1), 77–82 (1995)PubMed
39.
Zurück zum Zitat D.R. Rubinow, R.M. Post, R. Savard, P.W. Gold, Cortisol hypersecretion and cognitive impairment in depression. Arch. Gen. Psychiatry 41, 279–283 (1984)PubMed D.R. Rubinow, R.M. Post, R. Savard, P.W. Gold, Cortisol hypersecretion and cognitive impairment in depression. Arch. Gen. Psychiatry 41, 279–283 (1984)PubMed
40.
Zurück zum Zitat J.K. Belanoff, M. Kalehzan, B. Sund, S.K. Fleming Ficek, A.F. Schatzberg, Cortisol activity and cognitive changes in psychotic major depression. Am. J. Psychiatry 158, 1612–1616 (2001)PubMed J.K. Belanoff, M. Kalehzan, B. Sund, S.K. Fleming Ficek, A.F. Schatzberg, Cortisol activity and cognitive changes in psychotic major depression. Am. J. Psychiatry 158, 1612–1616 (2001)PubMed
41.
Zurück zum Zitat B. Siegel, D. Gurevich, G.F. Oxenkrug, Cognitive impairment and cortisol resistance to dexamethasone suppression in elderly depression. Biol. Psychiatry 25, 229–234 (1989)PubMed B. Siegel, D. Gurevich, G.F. Oxenkrug, Cognitive impairment and cortisol resistance to dexamethasone suppression in elderly depression. Biol. Psychiatry 25, 229–234 (1989)PubMed
42.
Zurück zum Zitat J. Wauthy, M. Ansseau, R. von Frenckell, C. Mormont, J.J. Legros, Memory disturbances and dexamethasone suppression test in major depression. Biol. Psychiatry 30, 736–738 (1991)PubMed J. Wauthy, M. Ansseau, R. von Frenckell, C. Mormont, J.J. Legros, Memory disturbances and dexamethasone suppression test in major depression. Biol. Psychiatry 30, 736–738 (1991)PubMed
43.
Zurück zum Zitat G. Winokur, D.W. Black, A. Nasrallah, DST nonsuppressor status: relationship to specific aspects of the depressive syndrome. Biol. Psychiatry 22, 360–368 (1987)PubMed G. Winokur, D.W. Black, A. Nasrallah, DST nonsuppressor status: relationship to specific aspects of the depressive syndrome. Biol. Psychiatry 22, 360–368 (1987)PubMed
44.
Zurück zum Zitat A. Georgotas, R.E. McCue, O.M. Kim, W.E. Hapworth, B. Reisberg, P.M. Stoll, E. Sinaiko, C. Fanelli, P.E. Stokes, Dexamethasone suppression in dementia, depression, and normal aging. Am. J. Psychiatry 143, 452–456 (1986)PubMed A. Georgotas, R.E. McCue, O.M. Kim, W.E. Hapworth, B. Reisberg, P.M. Stoll, E. Sinaiko, C. Fanelli, P.E. Stokes, Dexamethasone suppression in dementia, depression, and normal aging. Am. J. Psychiatry 143, 452–456 (1986)PubMed
45.
Zurück zum Zitat D.A. Axelson, P.M. Doraiswamy, W.M. McDonald, O.B. Boyko, L.A. Tupler, L.J. Patterson, C.B. Nemeroff, E.H. Ellinwood Jr, K.R. Krishnan, Hypercortisolemia and hippocampal changes in depression. Psychiatry Res. 47, 163–173 (1993)PubMed D.A. Axelson, P.M. Doraiswamy, W.M. McDonald, O.B. Boyko, L.A. Tupler, L.J. Patterson, C.B. Nemeroff, E.H. Ellinwood Jr, K.R. Krishnan, Hypercortisolemia and hippocampal changes in depression. Psychiatry Res. 47, 163–173 (1993)PubMed
46.
Zurück zum Zitat G. Cizza, P. Ravn, G.P. Chrousos, P.W. Gold, Depression: a major, unrecognized risk factor for osteoporosis? Trends Endocrinol. Metab. 12, 198–203 (2001)PubMed G. Cizza, P. Ravn, G.P. Chrousos, P.W. Gold, Depression: a major, unrecognized risk factor for osteoporosis? Trends Endocrinol. Metab. 12, 198–203 (2001)PubMed
47.
Zurück zum Zitat G. Cizza, S. Primma, G. Csako, Depression as a risk factor for osteoporosis. Trends Endocrinol. Metab. 20, 367–373 (2009)PubMedCentralPubMed G. Cizza, S. Primma, G. Csako, Depression as a risk factor for osteoporosis. Trends Endocrinol. Metab. 20, 367–373 (2009)PubMedCentralPubMed
48.
Zurück zum Zitat K.M. Yazici, A. Akinci, A. Sütçü, L. Ozçakar, Bone mineral density in premenopausal women with major depressive disorder. Psychiatry Res. 117, 271–275 (2003)PubMed K.M. Yazici, A. Akinci, A. Sütçü, L. Ozçakar, Bone mineral density in premenopausal women with major depressive disorder. Psychiatry Res. 117, 271–275 (2003)PubMed
49.
Zurück zum Zitat J.D. Amsterdam, M.B. Hooper, Bone density measurement in major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 22, 267–277 (1998)PubMed J.D. Amsterdam, M.B. Hooper, Bone density measurement in major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 22, 267–277 (1998)PubMed
50.
Zurück zum Zitat D. Michelson, C. Stratakis, L. Hill, J. Reynolds, E. Galliven, G. Chrousos, P. Gold, Bone mineral density in women with depression. N. Engl. J. Med. 335, 1176–1181 (1996)PubMed D. Michelson, C. Stratakis, L. Hill, J. Reynolds, E. Galliven, G. Chrousos, P. Gold, Bone mineral density in women with depression. N. Engl. J. Med. 335, 1176–1181 (1996)PubMed
51.
Zurück zum Zitat O. Altindag, A. Altindag, M. Asoglu, M. Gunes, N. Soran, Z. Deveci, Relation of cortisol levels and bone mineral density among premenopausal women with major depression. Int. J. Clin. Pract. 61, 416–420 (2007)PubMed O. Altindag, A. Altindag, M. Asoglu, M. Gunes, N. Soran, Z. Deveci, Relation of cortisol levels and bone mineral density among premenopausal women with major depression. Int. J. Clin. Pract. 61, 416–420 (2007)PubMed
52.
Zurück zum Zitat U. Halbreich, N. Rojansky, S. Palter, M. Hreshchyshyn, J. Kreeger, Y. Bakhai, R. Rosan, Decreased bone mineral density in medicated psychiatric patients. Psychosom. Med. 57, 485–491 (1995)PubMed U. Halbreich, N. Rojansky, S. Palter, M. Hreshchyshyn, J. Kreeger, Y. Bakhai, R. Rosan, Decreased bone mineral density in medicated psychiatric patients. Psychosom. Med. 57, 485–491 (1995)PubMed
53.
Zurück zum Zitat F. Eskandari, P.E. Martinez, S. Torvik, T.M. Phillips, E.M. Sternberg, S. Mistry, D. Ronsaville, R. Wesley, C. Toomey, N.G. Sebring, J.C. Reynolds, M.R. Blackman, K.A. Calis, P.W. Gold, G. Cizza, Premenopausal, Osteoporosis Women, Alendronate, Depression (POWER) Study Group, Low bone mass in premenopausal women with depression. Arch. Intern. Med. 167, 2329–2336 (2007)PubMed F. Eskandari, P.E. Martinez, S. Torvik, T.M. Phillips, E.M. Sternberg, S. Mistry, D. Ronsaville, R. Wesley, C. Toomey, N.G. Sebring, J.C. Reynolds, M.R. Blackman, K.A. Calis, P.W. Gold, G. Cizza, Premenopausal, Osteoporosis Women, Alendronate, Depression (POWER) Study Group, Low bone mass in premenopausal women with depression. Arch. Intern. Med. 167, 2329–2336 (2007)PubMed
54.
Zurück zum Zitat M.A. Tichomirowa, M.E. Keck, H.J. Schneider, M. Paez-Pereda, U. Renner, F. Holsboer, G.K. Stalla, Endocrine disturbances in depression. J. Endocrinol. Invest. 28, 89–99 (2005)PubMed M.A. Tichomirowa, M.E. Keck, H.J. Schneider, M. Paez-Pereda, U. Renner, F. Holsboer, G.K. Stalla, Endocrine disturbances in depression. J. Endocrinol. Invest. 28, 89–99 (2005)PubMed
55.
Zurück zum Zitat W. Pitchot, J. Reggers, E. Pinto, M. Hansenne, M. Ansseau, Catecholamine and HPA axis dysfunction in depression: relationship with suicidal behavior. Neuropsychobiology 47, 152–157 (2003)PubMed W. Pitchot, J. Reggers, E. Pinto, M. Hansenne, M. Ansseau, Catecholamine and HPA axis dysfunction in depression: relationship with suicidal behavior. Neuropsychobiology 47, 152–157 (2003)PubMed
56.
Zurück zum Zitat E. Syvälahti, Dexamethasone suppression test and the levels of serum growth hormone, plasma vasopressin and plasma homovanillic acid in depressed in- and out-patients. Acta Psychiatr. Scand. 71, 105–110 (1985)PubMed E. Syvälahti, Dexamethasone suppression test and the levels of serum growth hormone, plasma vasopressin and plasma homovanillic acid in depressed in- and out-patients. Acta Psychiatr. Scand. 71, 105–110 (1985)PubMed
57.
Zurück zum Zitat F. Contreras, J.M. Menchon, M. Urretavizcaya, M.A. Navarro, J. Vallejo, G. Parker, Hormonal differences between psychotic and non-psychotic melancholic depression. J. Affect. Disord. 100, 65–73 (2007)PubMed F. Contreras, J.M. Menchon, M. Urretavizcaya, M.A. Navarro, J. Vallejo, G. Parker, Hormonal differences between psychotic and non-psychotic melancholic depression. J. Affect. Disord. 100, 65–73 (2007)PubMed
58.
Zurück zum Zitat K. O’Flynn, T.G. Dinan, Baclofen-induced growth hormone release in major depression: relationship to dexamethasone suppression test result. Am. J. Psychiatry 150, 1728–1730 (1993)PubMed K. O’Flynn, T.G. Dinan, Baclofen-induced growth hormone release in major depression: relationship to dexamethasone suppression test result. Am. J. Psychiatry 150, 1728–1730 (1993)PubMed
59.
Zurück zum Zitat R.J. Dolan, S.P. Calloway, The human growth hormone response to clonidine: relationship to clinical and neuroendocrine profile in depression. Am. J. Psychiatry 143, 772–774 (1986)PubMed R.J. Dolan, S.P. Calloway, The human growth hormone response to clonidine: relationship to clinical and neuroendocrine profile in depression. Am. J. Psychiatry 143, 772–774 (1986)PubMed
60.
Zurück zum Zitat F. Duval, M.C. Mokrani, J.P. Macher, Reply to letter to the editor. Psychoneuroendocrinology 32, 211–212 (2007) F. Duval, M.C. Mokrani, J.P. Macher, Reply to letter to the editor. Psychoneuroendocrinology 32, 211–212 (2007)
61.
Zurück zum Zitat S.D. Targum, A.C. Sullivan, S.M. Byrnes, Neuroendocrine interrelationships in major depressive disorder. Am. J. Psychiatry 139, 282–286 (1982)PubMed S.D. Targum, A.C. Sullivan, S.M. Byrnes, Neuroendocrine interrelationships in major depressive disorder. Am. J. Psychiatry 139, 282–286 (1982)PubMed
62.
Zurück zum Zitat C. Kirkegaard, B.J. Carroll, Dissociation of TSH adrenocortical disturbances in endogenous depression. Psychiatry Res. 3, 253–264 (1980)PubMed C. Kirkegaard, B.J. Carroll, Dissociation of TSH adrenocortical disturbances in endogenous depression. Psychiatry Res. 3, 253–264 (1980)PubMed
64.
Zurück zum Zitat M. Maes, M. Vandewoude, L. Maes, C. Schotte, P. Cosyns, A revised interpretation of the TRH test results in female depressed patients. Part I: TSH responses. Effects of severity of illness, thyroid hormones, monoamines, age, sex hormonal, corticosteroid and nutritional state. J. Affect. Disord. 16, 203–213 (1989)PubMed M. Maes, M. Vandewoude, L. Maes, C. Schotte, P. Cosyns, A revised interpretation of the TRH test results in female depressed patients. Part I: TSH responses. Effects of severity of illness, thyroid hormones, monoamines, age, sex hormonal, corticosteroid and nutritional state. J. Affect. Disord. 16, 203–213 (1989)PubMed
65.
Zurück zum Zitat H. Agren, L. Wide, TRH tests with analyses of TSH, prolactin, and GH responses in subtypes of patients with major depressive disorders. Acta Psychiatr. Scand. 73, 549–558 (1986)PubMed H. Agren, L. Wide, TRH tests with analyses of TSH, prolactin, and GH responses in subtypes of patients with major depressive disorders. Acta Psychiatr. Scand. 73, 549–558 (1986)PubMed
66.
Zurück zum Zitat L. Bartalena, G.F. Placidi, E. Martino, M. Falcone, L. Pellegrini, L. Dell’Osso, A. Pacchiarotti, A. Pinchera, Nocturnal serum thyrotropin (TSH) surge and the TSH response to TSH-releasing hormone: dissociated behavior in untreated depressives. J. Clin. Endocrinol. Metab. 71, 650–655 (1990)PubMed L. Bartalena, G.F. Placidi, E. Martino, M. Falcone, L. Pellegrini, L. Dell’Osso, A. Pacchiarotti, A. Pinchera, Nocturnal serum thyrotropin (TSH) surge and the TSH response to TSH-releasing hormone: dissociated behavior in untreated depressives. J. Clin. Endocrinol. Metab. 71, 650–655 (1990)PubMed
67.
Zurück zum Zitat A.J. Rush, D.E. Giles, M.A. Schlesser, P.J. Orsulak, J.E. Weissenburger, C.L. Fulton, C.J. Fairchild, H.P. Roffwarg, Dexamethasone response, thyrotropin-releasing hormone stimulation, rapid eye movement latency, and subtypes of depression. Biol. Psychiatry 41, 915–928 (1997)PubMed A.J. Rush, D.E. Giles, M.A. Schlesser, P.J. Orsulak, J.E. Weissenburger, C.L. Fulton, C.J. Fairchild, H.P. Roffwarg, Dexamethasone response, thyrotropin-releasing hormone stimulation, rapid eye movement latency, and subtypes of depression. Biol. Psychiatry 41, 915–928 (1997)PubMed
68.
Zurück zum Zitat E.A. Young, A. Korszun, The hypothalamic-pituitary-gonadal axis in mood disorders. Endocrinol. Metab. Clin. North Am. 31, 63–78 (2002)PubMed E.A. Young, A. Korszun, The hypothalamic-pituitary-gonadal axis in mood disorders. Endocrinol. Metab. Clin. North Am. 31, 63–78 (2002)PubMed
69.
Zurück zum Zitat S.N. Seidman, S.P. Roose, The relationship between depression and erectile dysfunction. Curr. Psychiatry Rep. 2, 201–205 (2000)PubMed S.N. Seidman, S.P. Roose, The relationship between depression and erectile dysfunction. Curr. Psychiatry Rep. 2, 201–205 (2000)PubMed
70.
Zurück zum Zitat U. Schweiger, M. Deuschle, B. Weber, A. Körner, C.H. Lammers, J. Schmider, U. Gotthardt, I. Heuser, Testosterone, gonadotropin, and cortisol secretion in male patients with major depression. Psychosom. Med. 61, 292–296 (1999)PubMed U. Schweiger, M. Deuschle, B. Weber, A. Körner, C.H. Lammers, J. Schmider, U. Gotthardt, I. Heuser, Testosterone, gonadotropin, and cortisol secretion in male patients with major depression. Psychosom. Med. 61, 292–296 (1999)PubMed
71.
Zurück zum Zitat A. Steiger, U. von Bardeleben, K. Wiedemann, F. Holsboer, Sleep EEG and nocturnal secretion of testosterone and cortisol in patients with major endogenous depression during acute phase and after remission. J. Psychiatr. Res. 25, 169–177 (1991)PubMed A. Steiger, U. von Bardeleben, K. Wiedemann, F. Holsboer, Sleep EEG and nocturnal secretion of testosterone and cortisol in patients with major endogenous depression during acute phase and after remission. J. Psychiatr. Res. 25, 169–177 (1991)PubMed
72.
Zurück zum Zitat R.T. Rubin, R.E. Poland, I.M. Lesser, Neuroendocrine aspects of primary endogenous depression VIII. Pituitary-gonadal axis activity in male patients and matched control subjects. Psychoneuroendocrinology 14, 217–229 (1989)PubMed R.T. Rubin, R.E. Poland, I.M. Lesser, Neuroendocrine aspects of primary endogenous depression VIII. Pituitary-gonadal axis activity in male patients and matched control subjects. Psychoneuroendocrinology 14, 217–229 (1989)PubMed
73.
Zurück zum Zitat D.F. Swaab, A.M. Bao, P.J. Lucassen, The stress system in the human brain in depression and neurodegeneration. Ageing Res. Rev. 4, 141–194 (2005)PubMed D.F. Swaab, A.M. Bao, P.J. Lucassen, The stress system in the human brain in depression and neurodegeneration. Ageing Res. Rev. 4, 141–194 (2005)PubMed
74.
Zurück zum Zitat F. Petraglia, S. Sutton, W. Vale, P. Plotsky, Corticotropin-releasing factor decreases plasma luteinizing hormone levels in female rats by inhibiting gonadotropin-releasing hormone release into hypophysial-portal circulation. Endocrinology 120, 1083–1088 (1987)PubMed F. Petraglia, S. Sutton, W. Vale, P. Plotsky, Corticotropin-releasing factor decreases plasma luteinizing hormone levels in female rats by inhibiting gonadotropin-releasing hormone release into hypophysial-portal circulation. Endocrinology 120, 1083–1088 (1987)PubMed
75.
Zurück zum Zitat E.L. Perez, J. Blouin, A. Blouin, The dexamethasone suppression test in bulimia: nonsuppression associated with depression and suboptimal weight. J. Clin. Psychiatry 49, 94–96 (1988)PubMed E.L. Perez, J. Blouin, A. Blouin, The dexamethasone suppression test in bulimia: nonsuppression associated with depression and suboptimal weight. J. Clin. Psychiatry 49, 94–96 (1988)PubMed
76.
Zurück zum Zitat N. Piran, S. Kennedy, P.E. Garfinkel, M. Owens, Affective disturbance in eating disorders. J. Nerv. Ment. Dis. 173, 395–400 (1985)PubMed N. Piran, S. Kennedy, P.E. Garfinkel, M. Owens, Affective disturbance in eating disorders. J. Nerv. Ment. Dis. 173, 395–400 (1985)PubMed
77.
Zurück zum Zitat E.A. Lawson, D. Donoho, K.K. Miller, M. Misra, E. Meenaghan, J. Lydecker, T. Wexler, D.B. Herzog, A. Klibanski, Hypercortisolemia is associated with severity of bone loss and depression in hypothalamic amenorrhea and anorexia nervosa. J. Clin. Endocrinol. Metab. 94, 4710–4716 (2009)PubMedCentralPubMed E.A. Lawson, D. Donoho, K.K. Miller, M. Misra, E. Meenaghan, J. Lydecker, T. Wexler, D.B. Herzog, A. Klibanski, Hypercortisolemia is associated with severity of bone loss and depression in hypothalamic amenorrhea and anorexia nervosa. J. Clin. Endocrinol. Metab. 94, 4710–4716 (2009)PubMedCentralPubMed
78.
Zurück zum Zitat K.R. Bruce, H. Steiger, M. Israël, P. Groleau, N.M. Ng Ying Kin, A.S. Ouellette, L. Sycz, G. Badawi, Cortisol responses on the dexamethasone suppression test among women with Bulimia-spectrum eating disorders: associations with clinical symptoms. Prog. Neuropsychopharmacol. Biol. Psychiatry 38, 241–246 (2012)PubMed K.R. Bruce, H. Steiger, M. Israël, P. Groleau, N.M. Ng Ying Kin, A.S. Ouellette, L. Sycz, G. Badawi, Cortisol responses on the dexamethasone suppression test among women with Bulimia-spectrum eating disorders: associations with clinical symptoms. Prog. Neuropsychopharmacol. Biol. Psychiatry 38, 241–246 (2012)PubMed
79.
Zurück zum Zitat R.G. Laessle, M. Fischer, M.M. Fichter, K.M. Pirke, J.C. Krieg, Cortisol levels and vigilance in eating disorder patients. Psychoneuroendocrinology 17, 475–484 (1992)PubMed R.G. Laessle, M. Fischer, M.M. Fichter, K.M. Pirke, J.C. Krieg, Cortisol levels and vigilance in eating disorder patients. Psychoneuroendocrinology 17, 475–484 (1992)PubMed
80.
Zurück zum Zitat C. Lauer, W. Schreiber, M. Berger, K.M. Pirke, F. Holsboer, J.C. Krieg, The effect of neuroendocrine secretion on brain morphology and EEG sleep in patients with eating disorders. Eur. Arch. Psychiatry Neurol. Sci. 238, 208–212 (1989)PubMed C. Lauer, W. Schreiber, M. Berger, K.M. Pirke, F. Holsboer, J.C. Krieg, The effect of neuroendocrine secretion on brain morphology and EEG sleep in patients with eating disorders. Eur. Arch. Psychiatry Neurol. Sci. 238, 208–212 (1989)PubMed
81.
Zurück zum Zitat D.K. Katzman, E.K. Lambe, D.J. Mikulis, J.N. Ridgley, D.S. Goldbloom, R.B. Zipursky, Cerebral gray matter and white matter volume deficits in adolescent girls with anorexia nervosa. J. Pediatr. 129, 794–803 (1996)PubMed D.K. Katzman, E.K. Lambe, D.J. Mikulis, J.N. Ridgley, D.S. Goldbloom, R.B. Zipursky, Cerebral gray matter and white matter volume deficits in adolescent girls with anorexia nervosa. J. Pediatr. 129, 794–803 (1996)PubMed
82.
Zurück zum Zitat J. Castro-Fornieles, N. Bargalló, L. Lázaro, S. Andrés, C. Falcon, M.T. Plana, C. Junqué, A cross-sectional and follow-up voxel-based morphometric MRI study in adolescent anorexia nervosa. J. Psychiatr. Res. 43, 331–340 (2009)PubMed J. Castro-Fornieles, N. Bargalló, L. Lázaro, S. Andrés, C. Falcon, M.T. Plana, C. Junqué, A cross-sectional and follow-up voxel-based morphometric MRI study in adolescent anorexia nervosa. J. Psychiatr. Res. 43, 331–340 (2009)PubMed
83.
Zurück zum Zitat G.D. Giordano, P. Renzetti, R.C. Parodi, L. Foppiani, F. Zandrino, G. Giordano, F. Sardanelli, Volume measurement with magnetic resonance imaging of hippocampus-amygdala formation in patients with anorexia nervosa. J. Endocrinol. Invest. 24, 510–514 (2001)PubMed G.D. Giordano, P. Renzetti, R.C. Parodi, L. Foppiani, F. Zandrino, G. Giordano, F. Sardanelli, Volume measurement with magnetic resonance imaging of hippocampus-amygdala formation in patients with anorexia nervosa. J. Endocrinol. Invest. 24, 510–514 (2001)PubMed
84.
Zurück zum Zitat J.A. Seed, R.A. Dixon, S.E. McCluskey, A.H. Young, Basal activity of the hypothalamic-pituitary-adrenal axis and cognitive function in anorexia nervosa. Eur. Arch. Psychiatry Clin. Neurosci. 250, 11–15 (2000)PubMed J.A. Seed, R.A. Dixon, S.E. McCluskey, A.H. Young, Basal activity of the hypothalamic-pituitary-adrenal axis and cognitive function in anorexia nervosa. Eur. Arch. Psychiatry Clin. Neurosci. 250, 11–15 (2000)PubMed
85.
Zurück zum Zitat J. Jolles, Neuropeptides and cognitive disorders. Prog. Brain Res. 65, 177–192 (1986)PubMed J. Jolles, Neuropeptides and cognitive disorders. Prog. Brain Res. 65, 177–192 (1986)PubMed
86.
Zurück zum Zitat E.A. Lawson, A. Klibanski, Endocrine abnormalities in anorexia nervosa. Nat. Clin. Pract. Endocrinol. Metab. 4, 407–414 (2008)PubMed E.A. Lawson, A. Klibanski, Endocrine abnormalities in anorexia nervosa. Nat. Clin. Pract. Endocrinol. Metab. 4, 407–414 (2008)PubMed
87.
Zurück zum Zitat J.R. Newton, C.P. Freeman, W.J. Hannan, S. Cowen, Osteoporosis and normal weight bulimia nervosa–which patients are at risk? J. Psychosom. Res. 37, 239–247 (1993)PubMed J.R. Newton, C.P. Freeman, W.J. Hannan, S. Cowen, Osteoporosis and normal weight bulimia nervosa–which patients are at risk? J. Psychosom. Res. 37, 239–247 (1993)PubMed
88.
Zurück zum Zitat S. Zipfel, M.J. Seibel, B. Löwe, P.J. Beumont, C. Kasperk, W. Herzog, Osteoporosis in eating disorders: a follow-up study of patients with anorexia and bulimia nervosa. J. Clin. Endocrinol. Metab. 86, 5227–5233 (2001)PubMed S. Zipfel, M.J. Seibel, B. Löwe, P.J. Beumont, C. Kasperk, W. Herzog, Osteoporosis in eating disorders: a follow-up study of patients with anorexia and bulimia nervosa. J. Clin. Endocrinol. Metab. 86, 5227–5233 (2001)PubMed
89.
Zurück zum Zitat F. Jacoangeli, A. Zoli, A. Taranto, F. Staar Mezzasalma, C. Ficoneri, S. Pierangeli, G. Menzinger, M.R. Bollea, Osteoporosis and anorexia nervosa: relative role of endocrine alterations and malnutrition. Eat. Weight. Disord. 7, 190–195 (2002)PubMed F. Jacoangeli, A. Zoli, A. Taranto, F. Staar Mezzasalma, C. Ficoneri, S. Pierangeli, G. Menzinger, M.R. Bollea, Osteoporosis and anorexia nervosa: relative role of endocrine alterations and malnutrition. Eat. Weight. Disord. 7, 190–195 (2002)PubMed
90.
Zurück zum Zitat B.M. Biller, V. Saxe, D.B. Herzog, D.I. Rosenthal, S. Holzman, A. Klibanski, Mechanisms of osteoporosis in adult and adolescent women with anorexia nervosa. J. Clin. Endocrinol. Metab. 68, 548–554 (1989)PubMed B.M. Biller, V. Saxe, D.B. Herzog, D.I. Rosenthal, S. Holzman, A. Klibanski, Mechanisms of osteoporosis in adult and adolescent women with anorexia nervosa. J. Clin. Endocrinol. Metab. 68, 548–554 (1989)PubMed
91.
Zurück zum Zitat K.A. Carmichael, D.H. Carmichael, Bone metabolism and osteopenia in eating disorders. Medicine (Baltimore) 74, 254–267 (1995) K.A. Carmichael, D.H. Carmichael, Bone metabolism and osteopenia in eating disorders. Medicine (Baltimore) 74, 254–267 (1995)
92.
Zurück zum Zitat M. Misra, R. Prabhakaran, K.K. Miller, M.A. Goldstein, D. Mickley, L. Clauss, P. Lockhart, J. Cord, D.B. Herzog, D.K. Katzman, A. Klibanski, Prognostic indicators of changes in bone density measures in adolescent girls with anorexia nervosa-II. J. Clin. Endocrinol. Metab. 93, 1292–1297 (2008)PubMedCentralPubMed M. Misra, R. Prabhakaran, K.K. Miller, M.A. Goldstein, D. Mickley, L. Clauss, P. Lockhart, J. Cord, D.B. Herzog, D.K. Katzman, A. Klibanski, Prognostic indicators of changes in bone density measures in adolescent girls with anorexia nervosa-II. J. Clin. Endocrinol. Metab. 93, 1292–1297 (2008)PubMedCentralPubMed
93.
Zurück zum Zitat S. Naessén, K. Carlström, R. Glant, H. Jacobsson, A.L. Hirschberg, Bone mineral density in bulimic women-influence of endocrine factors and previous anorexia. Eur. J. Endocrinol. 155, 245–251 (2006)PubMed S. Naessén, K. Carlström, R. Glant, H. Jacobsson, A.L. Hirschberg, Bone mineral density in bulimic women-influence of endocrine factors and previous anorexia. Eur. J. Endocrinol. 155, 245–251 (2006)PubMed
94.
Zurück zum Zitat ESHRE Capri Workshop Group, Nutrition and reproduction in women. Hum. Reprod. Update 12, 193–207 (2006) ESHRE Capri Workshop Group, Nutrition and reproduction in women. Hum. Reprod. Update 12, 193–207 (2006)
95.
Zurück zum Zitat U. Schweiger, K.M. Pirke, R.G. Laessle, M.M. Fichter, Gonadotropin secretion in bulimia nervosa. J. Clin. Endocrinol. Metab. 74, 1122–1127 (1992)PubMed U. Schweiger, K.M. Pirke, R.G. Laessle, M.M. Fichter, Gonadotropin secretion in bulimia nervosa. J. Clin. Endocrinol. Metab. 74, 1122–1127 (1992)PubMed
96.
Zurück zum Zitat M. Misra, K.K. Miller, J. Bjornson, A. Hackman, A. Aggarwal, J. Chung, M. Ott, D.B. Herzog, M.L. Johnson, A. Klibanski, Alterations in growth hormone secretory dynamics in adolescent girls with anorexia nervosa and effects on bone metabolism. J. Clin. Endocrinol. Metab. 88, 5615–5623 (2003)PubMed M. Misra, K.K. Miller, J. Bjornson, A. Hackman, A. Aggarwal, J. Chung, M. Ott, D.B. Herzog, M.L. Johnson, A. Klibanski, Alterations in growth hormone secretory dynamics in adolescent girls with anorexia nervosa and effects on bone metabolism. J. Clin. Endocrinol. Metab. 88, 5615–5623 (2003)PubMed
97.
Zurück zum Zitat R.K. Støving, J.D. Veldhuis, A. Flyvbjerg, J. Vinten, J. Hangaard, O.G. Koldkjaer, J. Kristiansen, C. Hagen, Jointly amplified basal and pulsatile growth hormone (GH) secretion and increased process irregularity in women with anorexia nervosa: indirect evidence for disruption of feedback regulation within the GH-insulin-like growth factor I axis. J. Clin. Endocrinol. Metab. 84, 2056–2063 (1999)PubMed R.K. Støving, J.D. Veldhuis, A. Flyvbjerg, J. Vinten, J. Hangaard, O.G. Koldkjaer, J. Kristiansen, C. Hagen, Jointly amplified basal and pulsatile growth hormone (GH) secretion and increased process irregularity in women with anorexia nervosa: indirect evidence for disruption of feedback regulation within the GH-insulin-like growth factor I axis. J. Clin. Endocrinol. Metab. 84, 2056–2063 (1999)PubMed
98.
Zurück zum Zitat C. Bannai, N. Kuzuya, Y. Koide, T. Fujita, M. Itakura, K. Kawai, K. Yamashita, Assessment of the relationship between serum thyroid hormone levels and peripheral metabolism in patients with anorexia nervosa. Endocrinol. Jpn. 35, 455–462 (1988)PubMed C. Bannai, N. Kuzuya, Y. Koide, T. Fujita, M. Itakura, K. Kawai, K. Yamashita, Assessment of the relationship between serum thyroid hormone levels and peripheral metabolism in patients with anorexia nervosa. Endocrinol. Jpn. 35, 455–462 (1988)PubMed
99.
Zurück zum Zitat H. Tamai, N. Kobayashi, S. Fukata, Y. Hirota, S. Matsubayashi, T. Nakagawa, M.C. Okimura, R.M. Walter Jr, L.F. Kumagai, Paradoxical responses of plasma cortisol, adrenocorticotropic hormone and growth hormone to thyrotropin-releasing hormone and luteinizing-hormone-releasing hormone in anorexia nervosa patients. Psychother. Psychosom. 46, 147–151 (1986)PubMed H. Tamai, N. Kobayashi, S. Fukata, Y. Hirota, S. Matsubayashi, T. Nakagawa, M.C. Okimura, R.M. Walter Jr, L.F. Kumagai, Paradoxical responses of plasma cortisol, adrenocorticotropic hormone and growth hormone to thyrotropin-releasing hormone and luteinizing-hormone-releasing hormone in anorexia nervosa patients. Psychother. Psychosom. 46, 147–151 (1986)PubMed
100.
Zurück zum Zitat S. Grinspoon, L. Thomas, K. Miller, S. Pitts, D. Herzog, A. Klibanski, Changes in regional fat redistribution and the effects of estrogen during spontaneous weight gain in women with anorexia nervosa. Am. J. Clin. Nutr. 73, 865–869 (2001)PubMed S. Grinspoon, L. Thomas, K. Miller, S. Pitts, D. Herzog, A. Klibanski, Changes in regional fat redistribution and the effects of estrogen during spontaneous weight gain in women with anorexia nervosa. Am. J. Clin. Nutr. 73, 865–869 (2001)PubMed
101.
Zurück zum Zitat L. Mayer, B.T. Walsh, R.N. Pierson Jr, S.B. Heymsfield, D. Gallagher, J. Wang, M.K. Parides, R.L. Leibel, M.P. Warren, E. Killory, D. Glasofer, Body fat redistribution after weight gain in women with anorexia nervosa. Am. J. Clin. Nutr. 81, 1286–1291 (2005)PubMed L. Mayer, B.T. Walsh, R.N. Pierson Jr, S.B. Heymsfield, D. Gallagher, J. Wang, M.K. Parides, R.L. Leibel, M.P. Warren, E. Killory, D. Glasofer, Body fat redistribution after weight gain in women with anorexia nervosa. Am. J. Clin. Nutr. 81, 1286–1291 (2005)PubMed
102.
Zurück zum Zitat J. Balldin, U. Berggren, K. Bokström, G. Lindstedt, J. Sjöberg, C. Wendestam, Dexamethasone suppression test in alcohol withdrawal: relationship to depression and liver function. Drug Alcohol Depend. 30, 175–179 (1992)PubMed J. Balldin, U. Berggren, K. Bokström, G. Lindstedt, J. Sjöberg, C. Wendestam, Dexamethasone suppression test in alcohol withdrawal: relationship to depression and liver function. Drug Alcohol Depend. 30, 175–179 (1992)PubMed
103.
Zurück zum Zitat M.T. Abou-Saleh, J. Merry, A. Coppen, Dexamethasone suppression test in alcoholism. Acta Psychiatr. Scand. 69, 112–116 (1984)PubMed M.T. Abou-Saleh, J. Merry, A. Coppen, Dexamethasone suppression test in alcoholism. Acta Psychiatr. Scand. 69, 112–116 (1984)PubMed
104.
Zurück zum Zitat S.K. Majumdar, G.K. Shaw, P.K. Bridges, Relationship between plasma cortisol concentrations and depression in chronic alcoholic patients. Drug Alcohol Depend 14, 45–49 (1984)PubMed S.K. Majumdar, G.K. Shaw, P.K. Bridges, Relationship between plasma cortisol concentrations and depression in chronic alcoholic patients. Drug Alcohol Depend 14, 45–49 (1984)PubMed
105.
Zurück zum Zitat A. Heinz, H. Weingartner, D. George, D. Hommer, O.M. Wolkowitz, M. Linnoila, Severity of depression in abstinent alcoholics is associated with monoamine metabolites and dehydroepiandrosterone-sulfate concentrations. Psychiatry Res. 89, 97–106 (1999)PubMed A. Heinz, H. Weingartner, D. George, D. Hommer, O.M. Wolkowitz, M. Linnoila, Severity of depression in abstinent alcoholics is associated with monoamine metabolites and dehydroepiandrosterone-sulfate concentrations. Psychiatry Res. 89, 97–106 (1999)PubMed
106.
Zurück zum Zitat N. Müller, M. Hoehe, H.E. Klein, G. Nieberle, H.P. Kapfhammer, F. May, O.A. Müller, M. Fichter, Endocrinological studies in alcoholics during withdrawal and after abstinence. Psychoneuroendocrinology 14, 113–123 (1989)PubMed N. Müller, M. Hoehe, H.E. Klein, G. Nieberle, H.P. Kapfhammer, F. May, O.A. Müller, M. Fichter, Endocrinological studies in alcoholics during withdrawal and after abstinence. Psychoneuroendocrinology 14, 113–123 (1989)PubMed
107.
Zurück zum Zitat M. Huntgeburth, H. Ten Freyhaus, S. Rosenkranz, Alcohol consumption and hypertension. Curr. Hypertens. Rep. 7, 180–185 (2005)PubMed M. Huntgeburth, H. Ten Freyhaus, S. Rosenkranz, Alcohol consumption and hypertension. Curr. Hypertens. Rep. 7, 180–185 (2005)PubMed
108.
Zurück zum Zitat J.F. Potter, L.T. Bannan, J.B. Saunders, M.C. Ingram, D.G. Beevers, Blood pressure and pressor mechanisms during alcohol withdrawal. J. Hypertens. Suppl. 1, 97–99 (1983)PubMed J.F. Potter, L.T. Bannan, J.B. Saunders, M.C. Ingram, D.G. Beevers, Blood pressure and pressor mechanisms during alcohol withdrawal. J. Hypertens. Suppl. 1, 97–99 (1983)PubMed
109.
Zurück zum Zitat L.T. Bannan, J.F. Potter, D.G. Beevers, J.B. Saunders, J.R. Walters, M.C. Ingram, Effect of alcohol withdrawal on blood pressure, plasma renin activity, aldosterone, cortisol and dopamine beta-hydroxylase. Clin. Sci. (Lond) 66, 659–663 (1984) L.T. Bannan, J.F. Potter, D.G. Beevers, J.B. Saunders, J.R. Walters, M.C. Ingram, Effect of alcohol withdrawal on blood pressure, plasma renin activity, aldosterone, cortisol and dopamine beta-hydroxylase. Clin. Sci. (Lond) 66, 659–663 (1984)
110.
Zurück zum Zitat D.B. Maurel, N. Boisseau, C.L. Benhamou, C. Jaffre, Alcohol and bone: review of dose effects and mechanisms. Osteoporos. Int. 23, 1–16 (2012)PubMed D.B. Maurel, N. Boisseau, C.L. Benhamou, C. Jaffre, Alcohol and bone: review of dose effects and mechanisms. Osteoporos. Int. 23, 1–16 (2012)PubMed
111.
Zurück zum Zitat R.M. Couch, Dissociation of cortisol and adrenal androgen secretion in poorly controlled insulin-dependent diabetes mellitus. Acta Endocrinol. (Copenh.) 127, 115–117 (1992) R.M. Couch, Dissociation of cortisol and adrenal androgen secretion in poorly controlled insulin-dependent diabetes mellitus. Acta Endocrinol. (Copenh.) 127, 115–117 (1992)
112.
Zurück zum Zitat T.B. Kaye, R.A. Rubin, A.B. Goldfine, K. Rajamani, B.T. Kinsley, U.M. Vischer, D.C. Simonson, Effect of glycemic control on the overnight dexamethasone suppression test in patients with diabetes mellitus. J. Clin. Endocrinol. Metab. 74, 640–644 (1992)PubMed T.B. Kaye, R.A. Rubin, A.B. Goldfine, K. Rajamani, B.T. Kinsley, U.M. Vischer, D.C. Simonson, Effect of glycemic control on the overnight dexamethasone suppression test in patients with diabetes mellitus. J. Clin. Endocrinol. Metab. 74, 640–644 (1992)PubMed
113.
Zurück zum Zitat J.I. Hudson, M.S. Hudson, A.J. Rothschild, L. Vignati, A.F. Schatzberg, J.C. Melby, Abnormal results of dexamethasone suppression tests in nondepressed patients with diabetes mellitus. Arch. Gen. Psychiatry 41, 1086–1089 (1984)PubMed J.I. Hudson, M.S. Hudson, A.J. Rothschild, L. Vignati, A.F. Schatzberg, J.C. Melby, Abnormal results of dexamethasone suppression tests in nondepressed patients with diabetes mellitus. Arch. Gen. Psychiatry 41, 1086–1089 (1984)PubMed
114.
Zurück zum Zitat A.A. Mosbah, N.A. Abd-Ellatif, E.I. Sorour, Influence of serum cortisol levels on glycemic control in children with type 1 diabetes. J. Egypt Soc. Parasitol. 41, 777–784 (2011)PubMed A.A. Mosbah, N.A. Abd-Ellatif, E.I. Sorour, Influence of serum cortisol levels on glycemic control in children with type 1 diabetes. J. Egypt Soc. Parasitol. 41, 777–784 (2011)PubMed
115.
Zurück zum Zitat G. Valsamakis, A. Anwar, J.W. Tomlinson, C.H. Shackleton, P.G. McTernan, R. Chetty, P.J. Wood, A.K. Banerjee, G. Holder, A.H. Barnett, P.M. Stewart, S. Kumar, 11beta-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 89, 4755–4761 (2004)PubMed G. Valsamakis, A. Anwar, J.W. Tomlinson, C.H. Shackleton, P.G. McTernan, R. Chetty, P.J. Wood, A.K. Banerjee, G. Holder, A.H. Barnett, P.M. Stewart, S. Kumar, 11beta-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 89, 4755–4761 (2004)PubMed
116.
Zurück zum Zitat S.B. Abraham, D. Rubino, N. Sinaii, S. Ramsey, L.K. Nieman, Cortisol, obesity and the metabolic syndrome: a cross-sectional study of obese subjects and review of the literature. Obesity 21, 105–117 (2013) S.B. Abraham, D. Rubino, N. Sinaii, S. Ramsey, L.K. Nieman, Cortisol, obesity and the metabolic syndrome: a cross-sectional study of obese subjects and review of the literature. Obesity 21, 105–117 (2013)
117.
Zurück zum Zitat K.M. Oltmanns, B. Dodt, B. Schultes, H.H. Raspe, U. Schweiger, J. Born, H.L. Fehm, A. Peters, Cortisol correlates with metabolic disturbances in a population study of type 2 diabetic patients. Eur. J. Endocrinol. 154, 325–331 (2006)PubMed K.M. Oltmanns, B. Dodt, B. Schultes, H.H. Raspe, U. Schweiger, J. Born, H.L. Fehm, A. Peters, Cortisol correlates with metabolic disturbances in a population study of type 2 diabetic patients. Eur. J. Endocrinol. 154, 325–331 (2006)PubMed
118.
Zurück zum Zitat E. Rask, B.R. Walker, S. Söderberg, D.E. Livingstone, M. Eliasson, O. Johnson, R. Andrew, T. Olsson, Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11 beta-hydroxysteroid dehydrogenase type 1 activity. J. Clin. Endocrinol. Metab. 87, 3330–3336 (2002)PubMed E. Rask, B.R. Walker, S. Söderberg, D.E. Livingstone, M. Eliasson, O. Johnson, R. Andrew, T. Olsson, Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11 beta-hydroxysteroid dehydrogenase type 1 activity. J. Clin. Endocrinol. Metab. 87, 3330–3336 (2002)PubMed
119.
Zurück zum Zitat R.S. Lindsay, D.J. Wake, S. Nair, J. Bunt, D.E. Livingstone, P.A. Permana, P.A. Tataranni, B.R. Walker, Subcutaneous adipose 11 beta-hydroxysteroid dehydrogenase type 1 activity and messenger ribonucleic acid levels are associated with adiposity and insulinemia in Pima Indians and Caucasians. J. Clin. Endocrinol. Metab. 88, 2738–2744 (2003)PubMed R.S. Lindsay, D.J. Wake, S. Nair, J. Bunt, D.E. Livingstone, P.A. Permana, P.A. Tataranni, B.R. Walker, Subcutaneous adipose 11 beta-hydroxysteroid dehydrogenase type 1 activity and messenger ribonucleic acid levels are associated with adiposity and insulinemia in Pima Indians and Caucasians. J. Clin. Endocrinol. Metab. 88, 2738–2744 (2003)PubMed
120.
Zurück zum Zitat L.L. Gathercole, P.M. Stewart, Targeting the pre-receptor metabolism of cortisol as a novel therapy in obesity and diabetes. J. Steroid Biochem. Mol. Biol. 122, 21–27 (2010)PubMed L.L. Gathercole, P.M. Stewart, Targeting the pre-receptor metabolism of cortisol as a novel therapy in obesity and diabetes. J. Steroid Biochem. Mol. Biol. 122, 21–27 (2010)PubMed
121.
Zurück zum Zitat R.C. Andrews, O. Rooyackers, B.R. Walker, Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J. Clin. Endocrinol. Metab. 88, 285–291 (2003)PubMed R.C. Andrews, O. Rooyackers, B.R. Walker, Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J. Clin. Endocrinol. Metab. 88, 285–291 (2003)PubMed
122.
Zurück zum Zitat M. Hawkins, D. Hunter, P. Kishore, S. Schwartz, M. Hompesch, G. Hollis, R. Levy, B. Williams, R. Huber, INCB013739, a selective inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1), improves insulin sensitivity and lowers plasma cholesterol over 28 days in patients with type 2 diabetes mellitus. Diabetes 57(Suppl 1), A99–A100 (2008). (Abstract 1) M. Hawkins, D. Hunter, P. Kishore, S. Schwartz, M. Hompesch, G. Hollis, R. Levy, B. Williams, R. Huber, INCB013739, a selective inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1), improves insulin sensitivity and lowers plasma cholesterol over 28 days in patients with type 2 diabetes mellitus. Diabetes 57(Suppl 1), A99–A100 (2008). (Abstract 1)
123.
Zurück zum Zitat R.M. Reynolds, J. Labad, M.W. Strachan, A. Braun, F.G. Fowkes, A.J. Lee, B.M. Frier, J.R. Seckl, B.R. Walker, J.F. Price, Edinburgh Type 2 Diabetes Study (ET2DS) Investigators, Elevated fasting plasma cortisol is associated with ischemic heart disease and its risk factors in people with type 2 diabetes: the Edinburgh type 2 diabetes study. J. Clin. Endocrinol. Metab. 95, 1602–1608 (2010)PubMedCentralPubMed R.M. Reynolds, J. Labad, M.W. Strachan, A. Braun, F.G. Fowkes, A.J. Lee, B.M. Frier, J.R. Seckl, B.R. Walker, J.F. Price, Edinburgh Type 2 Diabetes Study (ET2DS) Investigators, Elevated fasting plasma cortisol is associated with ischemic heart disease and its risk factors in people with type 2 diabetes: the Edinburgh type 2 diabetes study. J. Clin. Endocrinol. Metab. 95, 1602–1608 (2010)PubMedCentralPubMed
124.
Zurück zum Zitat M. Peppa-Patrikiou, M. Scordili, A. Antoniou, M. Giannaki, M. Dracopoulou, C. Dacou-Voutetakis, Carotid atherosclerosis in adolescents and young adults with IDDM. Relation to urinary endothelin, albumin, free cortisol, and other factors. Diabetes Care 21, 1004–1007 (1998)PubMed M. Peppa-Patrikiou, M. Scordili, A. Antoniou, M. Giannaki, M. Dracopoulou, C. Dacou-Voutetakis, Carotid atherosclerosis in adolescents and young adults with IDDM. Relation to urinary endothelin, albumin, free cortisol, and other factors. Diabetes Care 21, 1004–1007 (1998)PubMed
125.
Zurück zum Zitat C. Dacou-Voutetakis, M. Peppa-Patrikiou, M. Dracopoulou, Urinary free cortisol and its nyctohemeral variation in adolescents and young adults with IDDM: relation to endothelin 1 and indices of diabetic angiopathy. J. Pediatr. Endocrinol. Metab. 11, 437–445 (1998)PubMed C. Dacou-Voutetakis, M. Peppa-Patrikiou, M. Dracopoulou, Urinary free cortisol and its nyctohemeral variation in adolescents and young adults with IDDM: relation to endothelin 1 and indices of diabetic angiopathy. J. Pediatr. Endocrinol. Metab. 11, 437–445 (1998)PubMed
126.
Zurück zum Zitat I. Chiodini, G. Adda, A. Scillitani, F. Coletti, V. Morelli, S. Di Lembo, P. Epaminonda, B. Masserini, P. Beck-Peccoz, E. Orsi, B. Ambrosi, M. Arosio, Cortisol secretion in patients with type 2 diabetes: relationship with chronic complications. Diabetes Care 30, 83–88 (2007)PubMed I. Chiodini, G. Adda, A. Scillitani, F. Coletti, V. Morelli, S. Di Lembo, P. Epaminonda, B. Masserini, P. Beck-Peccoz, E. Orsi, B. Ambrosi, M. Arosio, Cortisol secretion in patients with type 2 diabetes: relationship with chronic complications. Diabetes Care 30, 83–88 (2007)PubMed
127.
Zurück zum Zitat A.M. Stranahan, T.V. Arumugam, R.G. Cutler, K. Lee, J.M. Egan, M.P. Mattson, Diabetes impairs hippocampal function through glucocorticoid-mediated effects on new and mature neurons. Nat. Neurosci. 11, 309–317 (2008)PubMedCentralPubMed A.M. Stranahan, T.V. Arumugam, R.G. Cutler, K. Lee, J.M. Egan, M.P. Mattson, Diabetes impairs hippocampal function through glucocorticoid-mediated effects on new and mature neurons. Nat. Neurosci. 11, 309–317 (2008)PubMedCentralPubMed
128.
Zurück zum Zitat H. Bruehl, O.T. Wolf, V. Sweat, A. Tirsi, S. Richardson, A. Convit, Modifiers of cognitive function and brain structure in middle-aged and elderly individuals with type 2 diabetes mellitus. Brain Res. 1280, 186–194 (2009)PubMedCentralPubMed H. Bruehl, O.T. Wolf, V. Sweat, A. Tirsi, S. Richardson, A. Convit, Modifiers of cognitive function and brain structure in middle-aged and elderly individuals with type 2 diabetes mellitus. Brain Res. 1280, 186–194 (2009)PubMedCentralPubMed
129.
Zurück zum Zitat R.M. Reynolds, M.W. Strachan, J. Labad, A.J. Lee, B.M. Frier, F.G. Fowkes, R. Mitchell, J.R. Seckl, I.J. Deary, B.R. Walker, J.F. Price, Edinburgh Type 2 Diabetes Study Investigators, Morning cortisol levels and cognitive abilities in people with type 2 diabetes: the Edinburgh type 2 diabetes study. Diabetes Care 33, 714–720 (2010)PubMedCentralPubMed R.M. Reynolds, M.W. Strachan, J. Labad, A.J. Lee, B.M. Frier, F.G. Fowkes, R. Mitchell, J.R. Seckl, I.J. Deary, B.R. Walker, J.F. Price, Edinburgh Type 2 Diabetes Study Investigators, Morning cortisol levels and cognitive abilities in people with type 2 diabetes: the Edinburgh type 2 diabetes study. Diabetes Care 33, 714–720 (2010)PubMedCentralPubMed
130.
Zurück zum Zitat T.C. Sandeep, J.L. Yau, A.M. MacLullich, J. Noble, I.J. Deary, B.R. Walker, J.R. Seckl, 11Beta-hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics. Proc. Natl. Acad. Sci. USA 101, 6734–6739 (2004)PubMedCentralPubMed T.C. Sandeep, J.L. Yau, A.M. MacLullich, J. Noble, I.J. Deary, B.R. Walker, J.R. Seckl, 11Beta-hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics. Proc. Natl. Acad. Sci. USA 101, 6734–6739 (2004)PubMedCentralPubMed
131.
Zurück zum Zitat M. Duong, J.I. Cohen, A. Convit, High cortisol levels are associated with low quality food choice in type 2 diabetes. Endocrine 41, 76–81 (2012)PubMedCentralPubMed M. Duong, J.I. Cohen, A. Convit, High cortisol levels are associated with low quality food choice in type 2 diabetes. Endocrine 41, 76–81 (2012)PubMedCentralPubMed
132.
Zurück zum Zitat M. Christ-Crain, B. Kola, F. Lolli, C. Fekete, D. Seboek, G. Wittmann, D. Feltrin, S.C. Igreja, S. Ajodha, J. Harvey-White, G. Kunos, B. Müller, F. Pralong, G. Aubert, G. Arnaldi, G. Giacchetti, M. Boscaro, A.B. Grossman, M. Korbonits, AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing’s syndrome. FASEB J. 22, 1672–1683 (2008)PubMed M. Christ-Crain, B. Kola, F. Lolli, C. Fekete, D. Seboek, G. Wittmann, D. Feltrin, S.C. Igreja, S. Ajodha, J. Harvey-White, G. Kunos, B. Müller, F. Pralong, G. Aubert, G. Arnaldi, G. Giacchetti, M. Boscaro, A.B. Grossman, M. Korbonits, AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing’s syndrome. FASEB J. 22, 1672–1683 (2008)PubMed
133.
Zurück zum Zitat H. Djursing, H.C. Nyholm, C. Hagen, L. Carstensen, L.M. Pedersen, Clinical and hormonal characteristics in women with anovulation and insulin-treated diabetes mellitus. Am. J. Obstet. Gynecol. 143, 876–882 (1982)PubMed H. Djursing, H.C. Nyholm, C. Hagen, L. Carstensen, L.M. Pedersen, Clinical and hormonal characteristics in women with anovulation and insulin-treated diabetes mellitus. Am. J. Obstet. Gynecol. 143, 876–882 (1982)PubMed
134.
Zurück zum Zitat G. Reimondo, A. Pia, B. Allasino, F. Tassone, S. Bovio, G. Borretta, A. Angeli, M. Terzolo, Screening of Cushing’s syndrome in adult patients with newly diagnosed diabetes mellitus. Clin. Endocrinol. (Oxf) 67, 225–229 (2007) G. Reimondo, A. Pia, B. Allasino, F. Tassone, S. Bovio, G. Borretta, A. Angeli, M. Terzolo, Screening of Cushing’s syndrome in adult patients with newly diagnosed diabetes mellitus. Clin. Endocrinol. (Oxf) 67, 225–229 (2007)
135.
Zurück zum Zitat B. Catargi, V. Rigalleau, A. Poussin, N. Ronci-Chaix, V. Bex, V. Vergnot, H. Gin, P. Roger, A. Tabarin, Occult Cushing’s syndrome in type-2 diabetes. J. Clin. Endocrinol. Metab. 88, 5808–5813 (2003)PubMed B. Catargi, V. Rigalleau, A. Poussin, N. Ronci-Chaix, V. Bex, V. Vergnot, H. Gin, P. Roger, A. Tabarin, Occult Cushing’s syndrome in type-2 diabetes. J. Clin. Endocrinol. Metab. 88, 5808–5813 (2003)PubMed
136.
Zurück zum Zitat M. Terzolo, G. Reimondo, I. Chiodini, R. Castello, R. Giordano, E. Ciccarelli, P. Limone, C. Crivellaro, I. Martinelli, M. Montini, O. Disoteo, B. Ambrosi, R. Lanzi, M. Arosio, S. Senni, A. Balestrieri, E. Solaroli, B. Madeo, R. De Giovanni, F. Strollo, R. Battista, A. Scorsone, V.A. Giagulli, D. Collura, A. Scillitani, R. Cozzi, M. Faustini-Fustini, A. Pia, R. Rinaldi, B. Allasino, G. Peraga, F. Tassone, P. Garofalo, E. Papini, G. Borretta, Screening of Cushing’s syndrome in outpatients with type 2 diabetes: results of a prospective multicentric study in Italy. J. Clin. Endocrinol. Metab. 97, 3467–3475 (2012)PubMed M. Terzolo, G. Reimondo, I. Chiodini, R. Castello, R. Giordano, E. Ciccarelli, P. Limone, C. Crivellaro, I. Martinelli, M. Montini, O. Disoteo, B. Ambrosi, R. Lanzi, M. Arosio, S. Senni, A. Balestrieri, E. Solaroli, B. Madeo, R. De Giovanni, F. Strollo, R. Battista, A. Scorsone, V.A. Giagulli, D. Collura, A. Scillitani, R. Cozzi, M. Faustini-Fustini, A. Pia, R. Rinaldi, B. Allasino, G. Peraga, F. Tassone, P. Garofalo, E. Papini, G. Borretta, Screening of Cushing’s syndrome in outpatients with type 2 diabetes: results of a prospective multicentric study in Italy. J. Clin. Endocrinol. Metab. 97, 3467–3475 (2012)PubMed
137.
Zurück zum Zitat I. Chiodini, M. Torlontano, A. Scillitani, M. Arosio, S. Bacci, S. Di Lembo, P. Epaminonda, G. Augello, R. Enrini, B. Ambrosi, G. Adda, V. Trischitta, Association of subclinical hypercortisolism with type 2 diabetes mellitus: a case–control study in hospitalized patients. Eur. J. Endocrinol. 153, 837–844 (2005)PubMed I. Chiodini, M. Torlontano, A. Scillitani, M. Arosio, S. Bacci, S. Di Lembo, P. Epaminonda, G. Augello, R. Enrini, B. Ambrosi, G. Adda, V. Trischitta, Association of subclinical hypercortisolism with type 2 diabetes mellitus: a case–control study in hospitalized patients. Eur. J. Endocrinol. 153, 837–844 (2005)PubMed
138.
Zurück zum Zitat R. Pasquali, S. Cantobelli, F. Casimirri, M. Capelli, L. Bortoluzzi, R. Flamia, A.M. Labate, L. Barbara, The hypothalamic-pituitary-adrenal axis in obese women with different patterns of body fat distribution. J. Clin. Endocrinol. Metab. 77, 341–346 (1993)PubMed R. Pasquali, S. Cantobelli, F. Casimirri, M. Capelli, L. Bortoluzzi, R. Flamia, A.M. Labate, L. Barbara, The hypothalamic-pituitary-adrenal axis in obese women with different patterns of body fat distribution. J. Clin. Endocrinol. Metab. 77, 341–346 (1993)PubMed
139.
Zurück zum Zitat R. Rosmond, M.F. Dallman, P. Björntorp, Stress-related cortisol secretion in men: relationships with abdominal obesity and endocrine, metabolic and hemodynamic abnormalities. J. Clin. Endocrinol. Metab. 83, 1853–1859 (1998)PubMed R. Rosmond, M.F. Dallman, P. Björntorp, Stress-related cortisol secretion in men: relationships with abdominal obesity and endocrine, metabolic and hemodynamic abnormalities. J. Clin. Endocrinol. Metab. 83, 1853–1859 (1998)PubMed
140.
Zurück zum Zitat E. Torrecilla, G. Fernández-Vázquez, D. Vicent, F. Sánchez-Franco, A. Barabash, L. Cabrerizo, A. Sánchez-Pernaute, A.J. Torres, M.A. Rubio, Liver upregulation of genes involved in cortisol production and action is associated with metabolic syndrome in morbidly obese patients. Obes. Surg. 22, 478–486 (2012)PubMed E. Torrecilla, G. Fernández-Vázquez, D. Vicent, F. Sánchez-Franco, A. Barabash, L. Cabrerizo, A. Sánchez-Pernaute, A.J. Torres, M.A. Rubio, Liver upregulation of genes involved in cortisol production and action is associated with metabolic syndrome in morbidly obese patients. Obes. Surg. 22, 478–486 (2012)PubMed
141.
Zurück zum Zitat V. Vicennati, R. Pasquali, Abnormalities of the hypothalamic–pituitary–adrenal axis in nondepressed women with abdominal obesity and relations with insulin resistance: evidence for a central and a peripheral alteration. J. Clin. Endocrinol. Metab. 85, 4093–4098 (2000)PubMed V. Vicennati, R. Pasquali, Abnormalities of the hypothalamic–pituitary–adrenal axis in nondepressed women with abdominal obesity and relations with insulin resistance: evidence for a central and a peripheral alteration. J. Clin. Endocrinol. Metab. 85, 4093–4098 (2000)PubMed
142.
Zurück zum Zitat T. Reinehr, W. Andler, Cortisol and its relation to insulin resistance before and after weight loss in obese children. Horm. Res. 62, 107–112 (2004)PubMed T. Reinehr, W. Andler, Cortisol and its relation to insulin resistance before and after weight loss in obese children. Horm. Res. 62, 107–112 (2004)PubMed
143.
Zurück zum Zitat D.J. Wake, E. Rask, D.E. Livingstone, S. Söderberg, T. Olsson, B.R. Walker, Local and systemic impact of transcriptional up-regulation of 11 beta-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity. J. Clin. Endocrinol. Metab. 88, 3983–3988 (2003)PubMed D.J. Wake, E. Rask, D.E. Livingstone, S. Söderberg, T. Olsson, B.R. Walker, Local and systemic impact of transcriptional up-regulation of 11 beta-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity. J. Clin. Endocrinol. Metab. 88, 3983–3988 (2003)PubMed
144.
Zurück zum Zitat C. Wang, G. Jackson, T.H. Jones, A.M. Matsumoto, A. Nehra, M.A. Perelman, R.S. Swerdloff, A. Traish, M. Zitzmann, G. Cunningham, Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care 34, 1669–1675 (2011)PubMedCentralPubMed C. Wang, G. Jackson, T.H. Jones, A.M. Matsumoto, A. Nehra, M.A. Perelman, R.S. Swerdloff, A. Traish, M. Zitzmann, G. Cunningham, Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care 34, 1669–1675 (2011)PubMedCentralPubMed
145.
Zurück zum Zitat S. Wei, M.D. Schmidt, T. Dwyer, R.J. Norman, A.J. Venn, Obesity and menstrual irregularity: associations with SHBG, testosterone, and insulin. Obesity (Silver Spring). 17, 1070–1076 (2009)PubMed S. Wei, M.D. Schmidt, T. Dwyer, R.J. Norman, A.J. Venn, Obesity and menstrual irregularity: associations with SHBG, testosterone, and insulin. Obesity (Silver Spring). 17, 1070–1076 (2009)PubMed
146.
Zurück zum Zitat V. Vicennati, L. Ceroni, S. Genghini, L. Patton, U. Pagotto, R. Pasquali, Sex difference in the relationship between the hypothalamic–pituitary–adrenal axis and sex hormones in obesity. Obesity (Silver Spring). 14, 235–243 (2006)PubMed V. Vicennati, L. Ceroni, S. Genghini, L. Patton, U. Pagotto, R. Pasquali, Sex difference in the relationship between the hypothalamic–pituitary–adrenal axis and sex hormones in obesity. Obesity (Silver Spring). 14, 235–243 (2006)PubMed
147.
Zurück zum Zitat C.K. Buffington, J.R. Givens, A.E. Kitabchi, Enhanced adrenocortical activity as a contributing factor to diabetes in hyperandrogenic women. Metabolism 43, 584–590 (1994)PubMed C.K. Buffington, J.R. Givens, A.E. Kitabchi, Enhanced adrenocortical activity as a contributing factor to diabetes in hyperandrogenic women. Metabolism 43, 584–590 (1994)PubMed
148.
Zurück zum Zitat T. Grimmichová, J. Vrbíková, P. Matucha, K. Vondra, P.P. Veldhuis, M.L. Johnson, Fasting insulin pulsatile secretion in lean women with polycystic ovary syndrome. Physiol. Res. 57(Suppl 1), 91–98 (2008) T. Grimmichová, J. Vrbíková, P. Matucha, K. Vondra, P.P. Veldhuis, M.L. Johnson, Fasting insulin pulsatile secretion in lean women with polycystic ovary syndrome. Physiol. Res. 57(Suppl 1), 91–98 (2008)
149.
Zurück zum Zitat M. Hollingdal, C.B. Juhl, R. Dall, J. Sturis, J.D. Veldhuis, O. Schmitz, N. Pørksen, Glucocorticoid induced insulin resistance impairs basal but not glucose entrained high-frequency insulin pulsatility in humans. Diabetologia 45, 49–55 (2002)PubMed M. Hollingdal, C.B. Juhl, R. Dall, J. Sturis, J.D. Veldhuis, O. Schmitz, N. Pørksen, Glucocorticoid induced insulin resistance impairs basal but not glucose entrained high-frequency insulin pulsatility in humans. Diabetologia 45, 49–55 (2002)PubMed
150.
Zurück zum Zitat M. Zarković, J. Cirić, Z. Penezić, B. Trbojević, M. Drezgić, Temporal coupling of luteinizing hormone and follicle stimulating hormone secretion in polycystic ovary syndrome. Gynecol. Endocrinol. 15, 381–388 (2001)PubMed M. Zarković, J. Cirić, Z. Penezić, B. Trbojević, M. Drezgić, Temporal coupling of luteinizing hormone and follicle stimulating hormone secretion in polycystic ovary syndrome. Gynecol. Endocrinol. 15, 381–388 (2001)PubMed
151.
Zurück zum Zitat R. Pascualy, Sleep apnea and type 2 diabetes. A vicious circle. Diabetes Self. Manag. 24, 29–30 (2007)PubMed R. Pascualy, Sleep apnea and type 2 diabetes. A vicious circle. Diabetes Self. Manag. 24, 29–30 (2007)PubMed
152.
Zurück zum Zitat G. Copinschi, Metabolic and endocrine effects of sleep deprivation. Essent. Psychopharmacol. 6, 341–347 (2005)PubMed G. Copinschi, Metabolic and endocrine effects of sleep deprivation. Essent. Psychopharmacol. 6, 341–347 (2005)PubMed
153.
Zurück zum Zitat J.C. Lam, C.S. Yan, A.Y. Lai, S. Tam, D.Y. Fong, B. Lam, M.S. Ip, Determinants of daytime blood pressure in relation to obstructive sleep apnea in men. Lung 187, 291–298 (2009)PubMed J.C. Lam, C.S. Yan, A.Y. Lai, S. Tam, D.Y. Fong, B. Lam, M.S. Ip, Determinants of daytime blood pressure in relation to obstructive sleep apnea in men. Lung 187, 291–298 (2009)PubMed
154.
Zurück zum Zitat C. Parlapiano, M.C. Borgia, A. Minni, N. Alessandri, I. Basal, M. Saponara, Cortisol circadian rhythm and 24-hour Holter arterial pressure in OSAS patients. Endocr. Res. 31, 371–374 (2005)PubMed C. Parlapiano, M.C. Borgia, A. Minni, N. Alessandri, I. Basal, M. Saponara, Cortisol circadian rhythm and 24-hour Holter arterial pressure in OSAS patients. Endocr. Res. 31, 371–374 (2005)PubMed
155.
Zurück zum Zitat P.P. Roy-Byrne, T.W. Uhde, R.M. Post, W. Gallucci, G.P. Chrousos, P.W. Gold, The corticotropin-releasing hormone stimulation test in patients with panic disorder. Am. J. Psychiatry 143, 896–899 (1986)PubMed P.P. Roy-Byrne, T.W. Uhde, R.M. Post, W. Gallucci, G.P. Chrousos, P.W. Gold, The corticotropin-releasing hormone stimulation test in patients with panic disorder. Am. J. Psychiatry 143, 896–899 (1986)PubMed
156.
Zurück zum Zitat D.H. Avery, T.B. Osgood, D.M. Ishiki, L.G. Wilson, M. Kenny, D.L. Dunner, The DST in psychiatric outpatients with generalized anxiety disorder, panic disorder, or primary affective disorder. Am. J. Psychiatry 142, 844–848 (1985)PubMed D.H. Avery, T.B. Osgood, D.M. Ishiki, L.G. Wilson, M. Kenny, D.L. Dunner, The DST in psychiatric outpatients with generalized anxiety disorder, panic disorder, or primary affective disorder. Am. J. Psychiatry 142, 844–848 (1985)PubMed
157.
Zurück zum Zitat R.G. Kathol, R. Anton, R. Noyes, T. Gehris, Direct comparison of urinary free cortisol excretion in patients with depression and panic disorder. Biol. Psychiatry 25, 873–878 (1989)PubMed R.G. Kathol, R. Anton, R. Noyes, T. Gehris, Direct comparison of urinary free cortisol excretion in patients with depression and panic disorder. Biol. Psychiatry 25, 873–878 (1989)PubMed
158.
Zurück zum Zitat R.G. Kathol, R. Noyes Jr, A.L. Lopez, J.H. Reich, Relationship of urinary free cortisol levels in patients with panic disorder to symptoms of depression and agoraphobia. Psychiatry Res. 24, 211–221 (1988)PubMed R.G. Kathol, R. Noyes Jr, A.L. Lopez, J.H. Reich, Relationship of urinary free cortisol levels in patients with panic disorder to symptoms of depression and agoraphobia. Psychiatry Res. 24, 211–221 (1988)PubMed
159.
Zurück zum Zitat P. Westberg, K. Modigh, P. Lisjö, E. Eriksson, Higher postdexamethasone serum cortisol levels in agoraphobic than in nonagoraphobic panic disorder patients. Biol. Psychiatry 30, 247–256 (1991)PubMed P. Westberg, K. Modigh, P. Lisjö, E. Eriksson, Higher postdexamethasone serum cortisol levels in agoraphobic than in nonagoraphobic panic disorder patients. Biol. Psychiatry 30, 247–256 (1991)PubMed
160.
Zurück zum Zitat B. Bandelow, D. Wedekind, V. Sandvoss, A. Broocks, G. Hajak, J. Pauls, H. Peter, E. Rüther, Diurnal variation of cortisol in panic disorder. Psychiatry Res. 95, 245–250 (2000)PubMed B. Bandelow, D. Wedekind, V. Sandvoss, A. Broocks, G. Hajak, J. Pauls, H. Peter, E. Rüther, Diurnal variation of cortisol in panic disorder. Psychiatry Res. 95, 245–250 (2000)PubMed
161.
Zurück zum Zitat J.L. Abelson, G.C. Curtis, Hypothalamic–pituitary–adrenal axis activity in panic disorder. 24-hour secretion of corticotropin and cortisol. Arch. Gen. Psychiatry 53, 323–331 (1996)PubMed J.L. Abelson, G.C. Curtis, Hypothalamic–pituitary–adrenal axis activity in panic disorder. 24-hour secretion of corticotropin and cortisol. Arch. Gen. Psychiatry 53, 323–331 (1996)PubMed
162.
Zurück zum Zitat National Collaborating Centre for Mental Health (UK) Generalised Anxiety Disorder in Adults.: Management in Primary, Secondary and Community Care. pp 19. London: Royal College of Psychiatrists (2011) National Collaborating Centre for Mental Health (UK) Generalised Anxiety Disorder in Adults.: Management in Primary, Secondary and Community Care. pp 19. London: Royal College of Psychiatrists (2011)
163.
Zurück zum Zitat E.E. Schweizer, C.M. Swenson, A. Winokur, K. Rickels, G. Maislin, The dexamethasone suppression test in generalised anxiety disorder. Br. J. Psychiatry 149, 320–322 (1986)PubMed E.E. Schweizer, C.M. Swenson, A. Winokur, K. Rickels, G. Maislin, The dexamethasone suppression test in generalised anxiety disorder. Br. J. Psychiatry 149, 320–322 (1986)PubMed
164.
Zurück zum Zitat R.C. Mantella, M.A. Butters, J.A. Amico, S. Mazumdar, B.L. Rollman, A.E. Begley, C.F. Reynolds, E.J. Lenze, Salivary cortisol is associated with diagnosis and severity of late-life generalized anxiety disorder. Psychoneuroendocrinology 33, 773–781 (2008)PubMedCentralPubMed R.C. Mantella, M.A. Butters, J.A. Amico, S. Mazumdar, B.L. Rollman, A.E. Begley, C.F. Reynolds, E.J. Lenze, Salivary cortisol is associated with diagnosis and severity of late-life generalized anxiety disorder. Psychoneuroendocrinology 33, 773–781 (2008)PubMedCentralPubMed
165.
Zurück zum Zitat S.A. Vreeburg, F.G. Zitman, J. van Pelt, R.H. Derijk, J.C. Verhagen, R. van Dyck, W.J. Hoogendijk, J.H. Smit, B.W. Penninx, Salivary cortisol levels in persons with and without different anxiety disorders. Psychosom. Med. 72, 340–347 (2010)PubMed S.A. Vreeburg, F.G. Zitman, J. van Pelt, R.H. Derijk, J.C. Verhagen, R. van Dyck, W.J. Hoogendijk, J.H. Smit, B.W. Penninx, Salivary cortisol levels in persons with and without different anxiety disorders. Psychosom. Med. 72, 340–347 (2010)PubMed
167.
Zurück zum Zitat L. Manenschijn, R.G. van Kruysbergen, F.H. de Jong, J.W. Koper, E.F. van Rossum, Shift work at young age is associated with elevated long-term cortisol levels and body mass index. J. Clin. Endocrinol. Metab. 96, 1862–1865 (2011) L. Manenschijn, R.G. van Kruysbergen, F.H. de Jong, J.W. Koper, E.F. van Rossum, Shift work at young age is associated with elevated long-term cortisol levels and body mass index. J. Clin. Endocrinol. Metab. 96, 1862–1865 (2011)
168.
Zurück zum Zitat H. Raff, H. Trivedi, Circadian rhythm of salivary cortisol, plasma cortisol, and plasma ACTH in end-stage renal disease. Endocr. Connect. 19, 23–31 (2012) H. Raff, H. Trivedi, Circadian rhythm of salivary cortisol, plasma cortisol, and plasma ACTH in end-stage renal disease. Endocr. Connect. 19, 23–31 (2012)
169.
Zurück zum Zitat K. Carlström, A. Pousette, R. Stege, A. Lindholm, Serum hormone levels in men with end stage renal disease. Scand. J. Urol. Nephrol. 24, 75–78 (1990)PubMed K. Carlström, A. Pousette, R. Stege, A. Lindholm, Serum hormone levels in men with end stage renal disease. Scand. J. Urol. Nephrol. 24, 75–78 (1990)PubMed
170.
Zurück zum Zitat F. Hammer, N.C. Edwards, B.A. Hughes, R.P. Steeds, C.J. Ferro, J.N. Townend, P.M. Stewart, The effect of spironolactone upon corticosteroid hormone metabolism in patients with early stage chronic kidney disease. Clin. Endocrinol. (Oxf) 73, 566–572 (2010) F. Hammer, N.C. Edwards, B.A. Hughes, R.P. Steeds, C.J. Ferro, J.N. Townend, P.M. Stewart, The effect of spironolactone upon corticosteroid hormone metabolism in patients with early stage chronic kidney disease. Clin. Endocrinol. (Oxf) 73, 566–572 (2010)
171.
Zurück zum Zitat M. Walser, S. Hill, Effect of ketoconazole plus low-dose prednisone on progression of chronic renal failure. Am. J. Kidney Dis. 29, 503–513 (1997)PubMed M. Walser, S. Hill, Effect of ketoconazole plus low-dose prednisone on progression of chronic renal failure. Am. J. Kidney Dis. 29, 503–513 (1997)PubMed
172.
Zurück zum Zitat S.H. Shah, L.K. Newby, C-reactive protein: a novel marker of cardiovascular risk. Cardiol Rev. 11, 169–179 (2003)PubMed S.H. Shah, L.K. Newby, C-reactive protein: a novel marker of cardiovascular risk. Cardiol Rev. 11, 169–179 (2003)PubMed
173.
Zurück zum Zitat M.J. Sarnak, A.S. Levey, A.C. Schoolwerth, J. Coresh, B. Culleton, L.L. Hamm, P.A. McCullough, B.L. Kasiske, E. Kelepouris, M.J. Klag, P. Parfrey, M. Pfeffer, L. Raij, D.J. Spinosa, P.W. Wilson, American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention: kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Hypertension 42, 1050–1065 (2003)PubMed M.J. Sarnak, A.S. Levey, A.C. Schoolwerth, J. Coresh, B. Culleton, L.L. Hamm, P.A. McCullough, B.L. Kasiske, E. Kelepouris, M.J. Klag, P. Parfrey, M. Pfeffer, L. Raij, D.J. Spinosa, P.W. Wilson, American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention: kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Hypertension 42, 1050–1065 (2003)PubMed
174.
Zurück zum Zitat B.J. Carroll, A. Iranmanesh, D.M. Keenan, F. Cassidy, W.H. Wilson, J.D. Veldhuis, Pathophysiology of hypercortisolism in depression: pituitary and adrenal responses to low glucocorticoid feedback. Acta Psychiatr. Scand. 125, 478–491 (2012)PubMedCentralPubMed B.J. Carroll, A. Iranmanesh, D.M. Keenan, F. Cassidy, W.H. Wilson, J.D. Veldhuis, Pathophysiology of hypercortisolism in depression: pituitary and adrenal responses to low glucocorticoid feedback. Acta Psychiatr. Scand. 125, 478–491 (2012)PubMedCentralPubMed
175.
Zurück zum Zitat J. Licinio, M.L. Wong, P.W. Gold, The hypothalamic–pituitary–adrenal axis in anorexia nervosa. Psychiatry Res. 62, 75–83 (1996)PubMed J. Licinio, M.L. Wong, P.W. Gold, The hypothalamic–pituitary–adrenal axis in anorexia nervosa. Psychiatry Res. 62, 75–83 (1996)PubMed
176.
Zurück zum Zitat G.S. Birketvedt, E. Drivenes, I. Agledahl, J. Sundsfjord, R. Olstad, J.R. Florholmen, Bulimia nervosa: a primary defect in the hypothalamic–pituitary–adrenal axis? Appetite 46, 164–167 (2006)PubMed G.S. Birketvedt, E. Drivenes, I. Agledahl, J. Sundsfjord, R. Olstad, J.R. Florholmen, Bulimia nervosa: a primary defect in the hypothalamic–pituitary–adrenal axis? Appetite 46, 164–167 (2006)PubMed
177.
Zurück zum Zitat T.P. Beresford, D.B. Arciniegas, J. Alfers, L. Clapp, B. Martin, H.F. Beresford, Y. Du, D. Liu, D. Shen, C. Davatzikos, M.L. Laudenslager, Hypercortisolism in alcohol dependence and its relation to hippocampal volume loss. J. Stud. Alcohol 67, 861–867 (2006)PubMed T.P. Beresford, D.B. Arciniegas, J. Alfers, L. Clapp, B. Martin, H.F. Beresford, Y. Du, D. Liu, D. Shen, C. Davatzikos, M.L. Laudenslager, Hypercortisolism in alcohol dependence and its relation to hippocampal volume loss. J. Stud. Alcohol 67, 861–867 (2006)PubMed
178.
Zurück zum Zitat A. Smals, P. Kloppenborg, Alcohol-induced pseudo-Cushings syndrome. Lancet 1, 1369 (1977)PubMed A. Smals, P. Kloppenborg, Alcohol-induced pseudo-Cushings syndrome. Lancet 1, 1369 (1977)PubMed
179.
Zurück zum Zitat R.H. Stimson, R. Andrew, N.C. McAvoy, D. Tripathi, P.C. Hayes, B.R. Walker, Increased whole-body and sustained liver cortisol regeneration by 11 beta-hydroxysteroid dehydrogenase type 1 in obese men with type 2 diabetes provides a target for enzyme inhibition. Diabetes 60, 720–725 (2011)PubMedCentralPubMed R.H. Stimson, R. Andrew, N.C. McAvoy, D. Tripathi, P.C. Hayes, B.R. Walker, Increased whole-body and sustained liver cortisol regeneration by 11 beta-hydroxysteroid dehydrogenase type 1 in obese men with type 2 diabetes provides a target for enzyme inhibition. Diabetes 60, 720–725 (2011)PubMedCentralPubMed
180.
Zurück zum Zitat R. Pasquali, V. Vicennati, Activity of the hypothalamic-pituitary-adrenal axis in different obesity phenotypes. Int. J. Obes. Relat. Metab. Disord. 24(Suppl 2), 47–49 (2000) R. Pasquali, V. Vicennati, Activity of the hypothalamic-pituitary-adrenal axis in different obesity phenotypes. Int. J. Obes. Relat. Metab. Disord. 24(Suppl 2), 47–49 (2000)
181.
Zurück zum Zitat R. Pasquali, V. Vicennati, A. Gambineri, Adrenal and gonadal function in obesity. J. Endocrinol. Invest. 25, 893–898 (2002)PubMed R. Pasquali, V. Vicennati, A. Gambineri, Adrenal and gonadal function in obesity. J. Endocrinol. Invest. 25, 893–898 (2002)PubMed
182.
Zurück zum Zitat B.R. Walker, R. Andrew, Tissue production of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 and metabolic disease. Ann. N. Y. Acad. Sci. 1083, 165–184 (2006)PubMed B.R. Walker, R. Andrew, Tissue production of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 and metabolic disease. Ann. N. Y. Acad. Sci. 1083, 165–184 (2006)PubMed
183.
Zurück zum Zitat R. Desbriere, V. Vuaroqueaux, V. Achard, S. Boullu-Ciocca, M. Labuhn, A. Dutour, M. Grino, 11beta-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients. Obesity (Silver Spring) 14, 794–798 (2006) R. Desbriere, V. Vuaroqueaux, V. Achard, S. Boullu-Ciocca, M. Labuhn, A. Dutour, M. Grino, 11beta-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients. Obesity (Silver Spring) 14, 794–798 (2006)
184.
Zurück zum Zitat T. Tsilchorozidou, J.W. Honour, G.S. Conway, Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5 alpha-reduction but not the elevated adrenal steroid production rates. J. Clin. Endocrinol. Metab. 88, 5907–5913 (2003)PubMed T. Tsilchorozidou, J.W. Honour, G.S. Conway, Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5 alpha-reduction but not the elevated adrenal steroid production rates. J. Clin. Endocrinol. Metab. 88, 5907–5913 (2003)PubMed
185.
Zurück zum Zitat F. Roelfsema, P. Kok, A.M. Pereira, H. Pijl, Cortisol production rate is similarly elevated in obese women with or without the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 95, 3318–3324 (2010)PubMed F. Roelfsema, P. Kok, A.M. Pereira, H. Pijl, Cortisol production rate is similarly elevated in obese women with or without the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 95, 3318–3324 (2010)PubMed
186.
Zurück zum Zitat A. Gambineri, G. Forlani, A. Munarini, F. Tomassoni, G.E. Cognigni, W. Ciampaglia, U. Pagotto, B.R. Walker, R. Pasquali, Increased clearance of cortisol by 5 beta-reductase in a subgroup of women with adrenal hyperandrogenism in polycystic ovary syndrome. J. Endocrinol. Invest. 32, 210–218 (2009)PubMed A. Gambineri, G. Forlani, A. Munarini, F. Tomassoni, G.E. Cognigni, W. Ciampaglia, U. Pagotto, B.R. Walker, R. Pasquali, Increased clearance of cortisol by 5 beta-reductase in a subgroup of women with adrenal hyperandrogenism in polycystic ovary syndrome. J. Endocrinol. Invest. 32, 210–218 (2009)PubMed
187.
Zurück zum Zitat L.M. Tomfohr, K.M. Edwards, J.E. Dimsdale, Is obstructive sleep apnea associated with cortisol levels? A systematic review of the research evidence. Sleep Med. Rev. 16, 243–249 (2012)PubMedCentralPubMed L.M. Tomfohr, K.M. Edwards, J.E. Dimsdale, Is obstructive sleep apnea associated with cortisol levels? A systematic review of the research evidence. Sleep Med. Rev. 16, 243–249 (2012)PubMedCentralPubMed
188.
Zurück zum Zitat T.M. Buckley, A.F. Schatzberg, On the interactions of the hypothalamic–pituitary–adrenal (HPA) axis and sleep: normal HPA axis activity and circadian rhythm, exemplary sleep disorders. J. Clin. Endocrinol. Metab. 90, 3106–3114 (2005)PubMed T.M. Buckley, A.F. Schatzberg, On the interactions of the hypothalamic–pituitary–adrenal (HPA) axis and sleep: normal HPA axis activity and circadian rhythm, exemplary sleep disorders. J. Clin. Endocrinol. Metab. 90, 3106–3114 (2005)PubMed
189.
Zurück zum Zitat M. Clodi, M. Riedl, S. Schmaldienst, A. Vychytil, H. Kotzmann, A. Kaider, C. Bieglmayer, G. Mayer, W. Waldhäusl, A. Luger, Adrenal function in patients with chronic renal failure. Am. J. Kidney Dis. 32, 52–55 (1998)PubMed M. Clodi, M. Riedl, S. Schmaldienst, A. Vychytil, H. Kotzmann, A. Kaider, C. Bieglmayer, G. Mayer, W. Waldhäusl, A. Luger, Adrenal function in patients with chronic renal failure. Am. J. Kidney Dis. 32, 52–55 (1998)PubMed
Metadaten
Titel
Harmful effects of functional hypercortisolism: a working hypothesis
verfasst von
Giacomo Tirabassi
Marco Boscaro
Giorgio Arnaldi
Publikationsdatum
01.08.2014
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 3/2014
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-013-0112-y

Weitere Artikel der Ausgabe 3/2014

Endocrine 3/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.